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ABSTRACT 
 
The identification of novel mRNA and small RNA signatures of prognostic and 
diagnostic value in colorectal cancer (CRC) is primary focus of the thesis. The 
overall aim of the body this work is a deeper understanding of the molecular 
causes in the pathology of CRC and the identification of biomarkers, specifically 
mRNAs and other small non-coding RNAs with prognostic values in the clinical 
setting. These findings would in turn lead to an optimization of the therapeutic 
targets and ultimately to better clinical management of patients diagnosed with 
CRC. 
 
Next-generation sequencing (NGS) is based on deep sequencing, which produces 
billions of short sequences at a time. NGS benefits biomedical research in several 
ways by interrogating whole or partially targeted genomes, transcriptomes and 
epigenomes, including non-coding RNAs (ncRNAs) and microRNAs (miRs). NGS 
is able to rapidly generate large amounts of sequence data at substantially lower 
cost and time respect Sanger Sequencing. I have been involved in the 
development and application of various novel techniques for the construction of 
sample libraries for NGS analysis. I have also worked with various methods of 
analysis of next-generation sequencing data of cancer samples.  
 
In addition to NGS, I have also worked with numerous genomics technologies 
including, microarrays (both commercial and custom), NanoString, Real-Time 
PCR, protein arrays, and other genomics technologies to investigate not only 
colorectal cancer, but several other types of cancer including, but not limited to 
leukemia/lymphoma, breast cancer, head/neck cancer, osteosarcoma, and lung 
cancer.  
 
MicroRNAs are non-coding RNA regulators of protein output by way of coding 
RNA disruption. MicroRNAs have been shown to be differentially expressed in 
many solid cancers, and they can be considered biomarkers for predictive 
signatures in cancer. The effects of microRNAs are exerted on cell pathology and 
physiology controlling translation of tens or even hundreds of different coding 
messengers and a unique messenger can be controlled by more than one 
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microRNA. In turn, one, or more, microRNAs, can disrupt entire physiological 
pathways. 
 
Predictive markers are important in oncology as tumors of the same tissue of 
origin vary widely in their response to most available systemic therapies. Of all 
human cancers, colorectal cancer (CRC) is the third most commonly diagnosed 
cancer in the world at more than 500,000 new cases diagnosed per year.  
 
Currently, the Tumor-Node-Metastasis (TNM) is currently the most effective and 
reliable predictor of CRC outcomes. However, recently new genetic alterations 
have been uncovered which could potentially be used to estimate prognosis in 
CRC, with several of them potentially representing predictive markers towards 
appropriate treatment regimens. Unfortunately, most of these biomarkers have 
failed validation in the clinical setting, with some notable exceptions being loss-of-
function mutations in KRAS, BRAF, SMAD4 and TP53. In addition, there are 
genetic alterations such as chromosomal instability (CIN), loss of heterozygosity 
(LOH), micro-satellite instability (MSI), that affect mismatch repair (MMR) genes, 
including hMLH1, hMSH2, hMSH6, and PMS2. 
The overall predictive values of CIN and MSI remain controversial and the role of 
influence from mutations in other key genes involved in carcinogenesis still largely 
unclear.  
 
Short RNAs were sequenced from paired colon adenocarcinoma and normal 
samples. The RNA sequences were aligned on the human genome by using 
multiple independent algorithms. All short RNA sequences were de novo merged 
into more than 250,000 distinct RNA contigs covering the human genome. These 
de novo short RNA contigs, or shortigs, were then matched to human genome 
annotation. Using this unbiased genome wide approach, all short RNAs were 
profiled in colon adenocarcinoma. Alongside known miRNAs62, snoRNAs63, and 
piRNAs64, there were over 60 RNAs were differentially expressed from non-
annotated shortigs, and represented candidates for novel cancer non-coding 
genes. RNA expression plots were obtained for each shortig, revealing RNA 
processing of precursor miRNAs or even of entire miRNA clusters. A number of 
discrepancies with miRBase annotations were detected. The dynamic range and 
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specificity of next generation sequencing allowed an unprecedented insight into 
miRNA and other non-coding RNA expression in colorectal cancer. 
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INTRODUCTION 
 
Advances in Cancer 
 
Cancer is a multi-systemic disease with complex and varyingly mechanisms 
underlying the propagation of uncontrolled cellular growth across many tissue 
types. The onset and progression of all cancer are directly related to changes in 
the genome, which deregulate the normal control and oversight of DNA replication 
and cellular growth. These regulatory changes can manifest themselves as 
mutations and structural changes in the DNA or at the level of RNA expression 
and even epigenetic modulation, thus making cancer a disease entirely of genetic 
origin.  
 
In the past twenty years, progress in cancer research has had a significant impact 
on the diagnosis and prognosis of virtually all cancer of types. On the macro scale, 
methods for the detection, imaging and pathological screening of cancer have 
greatly improved and now routine examinations often lead to the early detection 
and in some cases the prevention of malignancy by removal of pre-cancerous 
masses. On a micro scale, many technological breakthroughs have had an 
explosive impact on our ability to study the genome (genomics) over the past three 
decades. Chiefly, the ability to better classify various cancers on a molecular basis 
has had the largest impact on cancer treatment and outcomes today. Advances in 
nucleic acid sequence and quantification, as well as the detection of epigenetic 
modulations throughout the genome have allowed micro classifications at the 
molecular level for various cancers. Additionally, on a broader scale, genomics 
research has led to better understanding of the fundamental mechanisms 
governing DNA replication and gene expression, particularly with the seminal 
revelation of the role of non-coding RNAs (ncRNAs) play in cancer and other 
disease progression by aberrant gene expression regulation. 
 
Collectively, these novel advances have allowed for the personalization of 
therapeutic intervention across cancers and many other diseases on the basis of 
these sub-classifications and re-classifications. The emergence of molecular 
stratifications combined with better clinical data have contributed to more complex 
profile analyses and the construction of large databases of molecular profiles sub-
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stratified on the basis of various genetic features (both somatic and hereditary), 
clinical outcomes, and treatment options. The expansions of these databases with 
continually increasing cohorts have ultimately proved invaluable in connecting 
molecular variation with disease manifestation and proliferation.  
 
However, the expectation that increasing the size of the data sets will increase the 
power to detect true cancer-related genetic driving events from the background of 
a multitude of seemingly random mutations has been frustratingly elusive. In fact, 
recent results seem to suggest the opposite phenomenon. The larger sample 
sizes produce huge indexes of apparently significant cancer-associated genes 
implausibly1. Therefore, our ability to fully utilize these molecular indexes and 
leverage them toward better treatment and prognosis of cancer hinges on our 
increasing ability to analyze and interrogate them. This is currently the frontier in 
genomics-related research in cancer as well as other types of diseases.  
 
Advances in Genomics Technologies 
 
Sequencing 
 
The field of genomics has been advancing at a rapid pace for the past two 
decades. There has been direct influence from the silicon chemistry industry and 
nano-fabrication processes on nucleic acid quantification along with novel 
advances in sequencing techniques built upon chain termination or chemical 
fragmentation, coupled with gel electrophoresis-based size separation methods 
originally developed by Nobel laureates Sanger and Gilbert2-4. The main difference 
between the Sanger and Maxam–Gilbert methods, was that the Sanger method 
employed the use of dideoxynucleotide triphosphates (ddNTPs) as DNA chain 
terminators, instead of chemically fragmenting the DNA before separation as the 
Maxam–Gilbert method calls for. Ultimately, the Sanger Method proved to be a 
more efficient and safer method because it required less toxic chemicals and 
reduced amounts of radioactivity compared with the chemical fragmentation 
method. The original Sanger reaction required a labeled-DNA primer (radioactively 
or fluorescently), a single-stranded template, DNA polymerase enzyme, as well as 
deoxy- and di-deoxy-nucleotides. The template was divided into four aliquots, 
having an equimolar mix of the polymerase enzyme and each of the four 
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deoxynucleotides (dATP, dGTP, dCTP and dTTP). One of the four chain-
terminating nucleotides in the di-deoxy form was added to each reaction to 
terminate DNA strand synthesis during the chain elongation step, which resulted in 
DNA fragments of various lengths. These fragments were pooled by reaction in 
separate wells (A, T, G, C) and subsequently separated on the basis of their size 
by denaturing them and migrating them through a poly-acrylamide gel slab by 
electrophoresis. After separation, the DNA bands were visualized either by either 
Ultra-violet light or autoradiography depending on the label used, fluorescence or 
radioactivity, respectively2-4. This method is also commonly referred to as First 
Generation Sequencing (FGS). 
 
From here, Sanger-based DNA sequencing has been marked by several key 
advances, including read automation; capillaries and multi-capillaries; replaceable 
polymer gel matrices. The first of these advances in sequencing came as Hood et 
al5 introduced primer-based sequencing with labeled di-deoxy-nucleotides (dye-
terminator) in a single reaction, which allowed for the fragments to be read 
optically. This would serve as the technological basis for which the Human 
Genome was initially sequenced. This technique was further improved with 
modified polymerases and better fluorescent with energy-transfer dyes (e.g., ABI 
Prism)6. 
 
The next significant advance in Sanger-based sequencing was the introduction of 
the capillary electrophoresis (CE), which proved to be a significant alternative to 
the more cumbersome and slower alternative of large slab gel electrophoresis. 
The first commercially available instrument was developed by Brownlee et al7,8. 
This first instrument was capable of detection in the UV/VIS spectrums with 
automated sample injection and delivery coupled with an on-board computer 
capable of a simple, but automated high-resolution analysis of the separated and 
differentially labeled DNA fragments9,10.  At this point, several instrument 
manufacturers begin to produce instruments based off this initial design. However, 
before these instruments could be used for true high-throughput analysis, some 
initial technical challenges involving thermal stability, the formation of bubbles in 
the gel matrices at the onset of electrophoresis, and most notably that the gel 
matrices were cross-linked needed to be addressed. Eventually, the formation of 
bubbles was addressed by a thermal adjustment and the problem of relatively 
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unstable cross-linked polymer gels was solved with the introduction of in-run 
replaceable gel chemistry. With these problems addressed, the result ultimately 
led an increase read accuracy and a marked improvement (several-fold decrease) 
in run times, which in turn, led to widespread use and distribution of these 
instruments.  
 
It became clear soon after that if the three billion bases in the human genome 
sequence were to be decoded, a larger format instrument with greater throughput 
capability was necessary.  The solution was developed by Mathies et al11, which 
produced the first multi-array capillary cartridge breakthrough capable of ninety-six 
simultaneous sequencing reactions through ninety-six capillary threads. However, 
this new capillary system required a more robust and sensitive alternative to the 
previous detection capabilities. One that could handle the simultaneous detection 
of all the capillaries and the resulting increases in light-scatter. Dovichi et al 
developed laser-based detector, which used a flowing cuvette to sheath the 
severe light-scattering which occurred with simultaneous detection of the gel 
threads, while Yeung et al12 first used an axial-beam excitation method which 
could focus the UV beam perpendicular across all the capillaries at once, which 
allowed for continuous CCD camera analysis across the entire array. This 
technology and these are methods are still primarily responsible for the majority of 
all Sanger-based sequencing today.  The CE method remains the standard for 
sequence validation and CE instruments can be found in nearly institution, as well 
as private sequencing facilities, around the world. 
 
Microarrays 
 
High-throughput genomics first came in the form of high-density DNA microarrays. 
Pat Brown et al13 first described the assembly of a custom fabricated microarray in 
the seminal publication in the journal Science in 1995 as a “high-capacity system 
to monitor the expression of many genes in parallel.” Prior to the development of 
this microarray technology, only a few gene transcripts could be PCR amplified 
and radio labeled to quantitate activity at a given time, in a method known as 
Northern Blot analysis.  The basis of the microarray is that complimentary nucleic 
acid sequences will preferentially bind to each other (G>C and A>T) within a 
heterogeneous population of nucleic acids. The first microarray was produced by 
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using a robotic printer to ‘blot’ an array of thousands of cDNA molecules 
complimentary to RNA transcripts for thousands of genes, with a method similar to 
that of ink jet printing13. The array of small blots of double stranded cDNA were 
first immobilized on a specially coated glass microscope slide (microarray) and 
then denatured prior to hybridization with mRNA derived cDNA. Two different 
mRNA transcripts from two different cell populations were reverse-transcribed into 
cDNA and end-labeled with either a red or green fluorescent dye label. Equimolar 
ratios of each sample were denatured and were allowed to competitively hybridize 
to the microarray. After washing, the microarray is optically scanned at two 
wavelengths to excite both dyes and the resulting images are combined into a 
single image. Where one sample had strongly hybridized to the array, the ratio of 
signal color either red or green, was indicative of differential gene expression 
between the two samples. If both samples had hybridized similarly to the array an 
even color mixture of yellow indicated little transcript change between samples. 
This method was known as a two-channel competitive hybridization microarray.  
Another important microarray technology was also being developed around the 
same time by Dr. Stephen Fodor and colleagues at Affymetrix, Inc., which 
implemented the use of light-directed chemolithography (similar to silicon wafer 
manufacturing) to place and secure millions of short oligo nucleotide sequences 
over a boron-slated glass surface to construct an ultra high-density microarray with 
significantly increased resolution compared to the aforementioned method 
developed by Brown. These types of microarray became known as GeneChips, 
with the first arrays being released to the public in 1996. GeneChips were sold as 
consumables, which required a microfluidics, station that carried out washing and 
staining steps and a special laser scanner originally developed in collaboration 
with Hewlett-Packard. In addition to the sizeable increase in resolution, this type of 
microarray technology relied on the complimentary binding of RNA to the 
oligonucleotides bound to glass surface of the array, instead of end-labeled cDNA 
employed by the Brown method. The GeneChip method initially relied on purified 
mRNA as the input source, which was then reversed-transcribed with a second-
strand subsequently generated to produce cDNA. At this point, the resulting cDNA 
was invitro-transcribed back in cRNA using biotinylated ribonucleotides and RNA 
polymerase. The labeled targets were then stained with a fluorescent conjugate 
(streptavidin-phycoerythrin solution). This signified a major departure from the 
Brown method as targets were all non-differentially labeled which meant that every 
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target sample needed a independent measurement, as opposed to a competitive 
hybridization. This became known as single-channel hybridization, with a more 
stable method for labeling and fluorescence measurement.  The Affymetrix 
GeneChips were also designed to serve as hybridization chambers and allowed 
the process of hybridization, washing/staining, and scanning procedures to be 
highly automated, reproducible, and in general, a faster method of microarray 
analysis compared to the Brown method14.  
Despite the many technological advantages that GeneChips have over custom 
manufactured microarrays, there are some advantages that custom arrays have 
over GeneChips, with the most obvious advantage being the ability to customize 
the content, which is critical for discovery work. It’s also an inexpensive alternative 
to GeneChips for rapid validation of a relatively small amount of content over large 
cohorts. GeneChips, while being customizable, are essentially limited in the scope 
of discovery and the content design of the array is dependent on sequence 
information being available. However, it is generally cost-prohibitive for many 
facilities to employ customized GeneChips in the repertoire, for those projects, 
which require the use of microarrays. 
 
Next-Generation Sequencing 
 
The traditional Sanger-based sequencing and capillary electrophoresis have some 
significant disadvantages for ultra high-throughput applications. The efficacy of the 
separation is limited and begins to drop off after around a thousand bases due to 
sieving capabilities of the matrix, the reactions are limited in terms of cost 
efficiency for high-coverage discovery-based experiments where repetitive 
sequence coverage is paramount for the identification of rare genetic events, 
especially in the analysis of heterogeneous cell population. Therefore, Sanger-
based CE sequencing has largely become import in more of a niche role, primarily 
for validation of clinical applications or small experiments. The challenge of 
handling the human genome needed a new approach. With the completion of the 
Human Genome Project in 2003, a project predominantly sequenced by the 
Sanger method at a cost of nearly three billion dollars over thirteen years, it 
became clear that faster and cheaper alternatives to FGS were necessary to take 
advantage of the newly cemented human template sequence. To interrogate 
sequence variation across scores of genes simultaneously in large cohorts 
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demanded a new way to sequence nucleic acid.  Next-generation sequencing 
(NGS) is huge shift in paradigm to that of the Sanger chemistry. Instead of 
separating the DNA by electrophoresis of the chain-terminated products one by 
one, the hallmark of the current NGS technologies are that they take advantage of 
massively parallel sequencing of clonally amplified DNA molecules, which have 
been immobilized, in wells across a single or multiple flow cells15. The immobilized 
DNA fragments are sequenced either by polymerase-mediated oligonucleotide 
extension or by serial ligation of oligonucleotide complexes of billions of fragments 
in parallel. The other main characteristic of NGS is the need to construction 
libraries. Prior to clonal amplification the template DNA (or RNA) is carefully 
fragmented either at the whole-genome or partial genome (or transcriptome) level. 
From here, adaptor sequences are ligated to both end of the fragments (single or 
double-stranded) and pre-amplified to create libraries of cDNA fragments flanked 
by adaptor inserts. These adaptors are involved in fragment immobilization, clonal 
amplification, or the sequencing reaction itself. The process of library building 
remains the most important step in NGS technology and can be among the most 
difficult components of all the NGS platforms today. 
 
The initial commercial platform for NGS on the market was launched as the GS-20 
produced by 454 Life Sciences in 2005. The GS 20 was primarily based on the 
principles of pyro-sequencing and emulsification PCR chemistry (ePCR). Pyro-
sequencing was first introduced by Nyren et al. in a 1993  landmark publication in 
which a method for  sequencing by the detection of chemiluminescent 
pyrophosphates released during polymerase-directed deoxynucleoside 
triphosphate (dNTP) incorporation was described16,17. 
Subsequent refinement by Ronaghi et al.18 a few years later would serve as 
principle technological basis for the first GS-20 NGS instrument from 454 LS.  
 
In 2007, Roche Applied Science purchased 454 Life Sciences and launched the 
an updated version of the 454 instrument, now known as the GS FLX. The GS 
FLX continues to rely on the principle library preparation strategy involving the use 
of cPCR to massively clonally amplify DNA fragments. In addition, the GS FLX 
also uses the same pico-titer well plate system employed by the original 
instrument, in which a microplate has fiber-optic bundles etched into the plates 
surface which serve as the wells in which the sequencing reactions take place. 
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The post ePCR amplified library products are then deposited into the individual 
pico-titer wells with the sequencing chemistry necessary for the subsequent 
pyrophosphate sequencing reactions. Several iterative additions of free dNTPs are 
flowed in an orderly manner through the wells of the pico-titer plate and with the 
incorporation of every individual nucleotide a pyrophosphate is released. This 
release generates a localized, well-dependent, chemiluminescence that is 
captured by a charge-coupled CCD camera (Figure 115). Images are gathered 
across the plate and software analyzed for their respective signal to-noise ratio 
and then the results are linearized into a common genetic sequence output19. The 
typical output from the GS FLX is approximately five-hundred million bases in total, 
with the average read length being >400 base-pairs. This represents the longest 
average read length among the three largest NGS platforms. The GS FLX has an 
enormous advantage in accurate sequence alignment (per read) over the other 
major platforms. It is for this reason, it remains the choice of de novo sequencing 
of small genomes, usually microbial for many projects15,20. Like all the NGS 
platforms, the sequence output is aligned to either a reference sequence and 
analyzed for differences, or a de novo assembly is made by stringing together 
overlapping sequences within the reads to produce reference scaffolds to be used 
as anchors when overlapping sequence is not available. There are some 
drawbacks to this platform. The cost is significantly higher per mb of output as 
compared with the other major platforms. Similarly, the relative output, or depth of 
coverage, per run makes this a difficult choice for human and other large genome 
sequencing projects, or studies with large cohorts. Although, the GS FLX with it’s 
long sequence reads, is considered the most accurate in terms of sequence 
alignment, but because of the nature of the chemiluminescence from 
pyrophosphate sequencing, the GS FLX has trouble distinguishing long stretches 
of homopolymers. Theoretically, a stretch of 8 adenines (or any of the other three 
bases) would have twice the chemiluminescence as 4 adjacent adenines, 
however, in practice this is not always the case and this makes it difficult to call 
single-nucleotide polymorphisms (SNPs) in repeated sequence elements19,21. 
 
 
 
 
The next major NGS platform to market was developed in 2006, called the 
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Genome Analyzer, developed and manufactured by Solexa, a company founded 
by Shankar Balasubramanian and David Klenerman, in Great Britain and later 
acquired by Illumina (http://www.Illumina.com) later that same year. As the original 
goal of single molecule sequencing was not achieved the duo decided to capitalize 
on clonal sequencing of short DNA fragments immobilized onto microspheres. 
This became the basis for the “short read” platform in NGS15. As the term ‘short 
read’ suggests, short DNA fragments are clonally amplified and subsequently 
sequenced producing billions of short reads, which are then algorithmically 
assembled into contiguous linear sequences known as contigs or shortigs. These 
contigs can either be built using assembly scaffolds of overlapping contigs for de  
novo sequencing or by directly aligning to a reference sequence for re-sequencing 
and directed re-sequencing projects, such as RNA-seq or Methyl-seq. The library 
generation requires that template DNA be uniformly fragmented (either by 
sonication, chemical or enzymatic restriction) and size selected if genomic DNA is 
the template, or another selection protocol as necessary, if re-sequencing of RNA 
or the targeting of DNA is required. Like the GS FLX library preparation, the 
resulting fragments are end-repaired to generate 5’-phosphorylated blunt ends. 
The enzymatic Klenow fragment is used to add a single Adenine base to the 3’-
end of the repaired DNA fragments. This allows the DNA fragments to be ligated 
to the oligonucleotide library adaptors with greater efficiency since these are 
manufactured with a single T base overhang at the 3’-end. The oligonucleotide 
library adaptors are complimentary to oligonucleotide anchors, which are 
immobilized on the surface of the glass sequencing slides within each of eight 
lanes or wells. These glass slides are known as ordered arrays or flow cells, and 
are optically transparent to allow for subsequent fluorescent detection (Figure 215). 
A fundamental difference between the Illumina platform and the ePCR-based 
methodologies is that the clonal amplification of the DNA fragments takes place on 
instrument in the wells of the sequencing slides, as opposed to an emulsion of 
PCR reagents and template which occurs off-instrument. The Illumina method 
relies on templates hybridizing to the anchor oligos and ‘arching’ or ‘bridging’ over 
and hybridizing to adjacent anchors within each well as the PCR reagents are 
flowed through the cell, more arches or bridges are formed and the entire process 
forms clusters of clonally amplified product from each DNA template. This type of 
amplification is commonly referred to as bridge amplification, and is heavily 
dependant on proper dilution of the template and the number of amplification 
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cycles used to prevent crowding and allow each DNA fragment cluster to amplify 
and grow without contaminating surrounding templates. The resulting clusters 
usually generate close to a thousand clonally amplified molecules. Each well 
typically has enough space without significant steric strain to house approximately 
50 x 106 individual clusters per flow cell (all lanes).  
The sequencing reaction is based on the incorporation of four reversible 
fluorescent dye terminators in the presence of DNA polymerase. Each dye 
terminator is indicative of each of the DNA bases (A,T,G,C). This is called 
sequencing by synthesis and sequencing in this manner can be performed in 
either the forward or reverse direction, depending on the primer used, since each 
of the cluster’s fragments have adaptors in both the forward and reverse 
directions. After the complimentary primers have been annealed, polymerase and 
an equimolar mixture of the labeled dye terminators are flowed the lanes of the 
flow cell with the addition of a labeled dNTP based on the complimentary 
sequence of each of the cluster’s fragments. The resulting fluorescence is optically 
measured and analyzed in real-time, after each successive addition of a dye 
terminator, the label is chemically cleaved, washed and a subsequent addition 
continues where the previous reaction left off. The result is a 50-100 base-pair 
sequence beginning from either the 5’- or the 3’- end (or a ‘paired-end’ approach if 
both ends are sequenced), for each of the molecules in a cluster across the entire 
flow cell. The entire process takes approximately three to six days to complete, 
dependent on whether or not both ends of the template fragments are sequenced. 
A typical sequencing run of this type produces one to two billion bases per flow 
cell, per run15,22. Improvements to this system are continuing with great frequency 
and the Gb output is expected to grow significantly in the next couple of years 
while the run times are also continuing to decrease. 
A major advantage of this type of short-read sequencing platform over the GS FLX 
is that is produces substantially more reads which in turn nets a deep depth of 
coverage (also known as deep sequencing). In addition, the overall output (Gb) is 
significantly greater than the long read platform with a similar run time, but less 
overall cost. For those experiments that require very deep sequencing, such as 
RNA-seq, small RNA-seq, methyl-seq and those where rare genomic events need 
to be examined, this short-read method has sizeable advantages over the long 
read GS FLX platform. There are also some disadvantages to this type of 
sequencing. For instance, it has been shown that the Illumina platform has greater 
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difficulty in accurately sequencing DNA with a higher G+C content that in turn 
creates a G+C bias across the read pool23. In addition, read accuracy begins to 
decrease as the size of the fragment increases, due to either incomplete blocking 
or incomplete cleavage of the labeled terminators resulting in the strand synthesis 
becoming ‘out-of-phase’ (also known as de-phased)24,25. This not only makes it 
difficult to correctly place a read into a reference source, but it also aberrantly 
creates false calls which are very difficult to measure from a bioinformatic point of 
view. This ultimately leads to a reduction in usable reads or to a high number of 
false negative or positive polymorphisms. However, better bioinformatic analysis 
techniques continue to improve the way these reads are analyzed, for example, it 
is worth noting that because these reads to progressively decrease in quality as 
the read progresses, it is possible to pinpoint the beginning pf the de-phasing by 
anchor the alignment of the reads into reduced read-length. This coupled with a 
‘paired-end’ sequencing approach help facilitate better alignment into a reference 
source26. While this is currently an informatics technique developed to deal with 
better alignment of lower quality reads, it doesn’t help to distinguish false calls 
within the read itself. Great strides in the field of bioinformatics are continuously 
being made and will ensure that the utility of the short-read platform will on 
increase as the technology moves forward into the future.  
 
 
The last of the major NGS platforms, came to commercial market in 2007, was the 
SOLiD system, manufactured by Applied Biosystems (now Life Technologies). It is 
considered a short-read platform, but shares considerable technological aspects 
with both of the aforementioned platforms, both in terms of overall capability and 
methodology. The basis of this sequencing platform was derived from polony-
sequencing, one of the first alternative sequencing strategies first described by the 
Church group (Harvard University) in their seminal publication in 200527. This 
method is able to massively sequence millions of DNA template strands in parallel, 
which have been randomly fragmented into ~150-250-bp lengths. These 
fragments are clonally amplified by emulsification PCR. The fragments are then 
immobilized and sequenced by ligases and polymerases. Primers are anchored to 
the templates and discriminatory ligation of fluorescently labeled degenerative 
nonamers takes place based on sequence affinity to the template sequence. At 
each position of the template sequence a new set of labeled nonamers is 
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introduced and the excitation of particular fluorofor is indicative of the type of base 
present at that location in the template.  
The library generation is very similar to the method used for the preparation of the 
GS FLX libraries in that adaptor sequences are ligated to both ends of the 
template sequence, which have been blunted with a single T overhang and 
phosphorylated prior to ligation.  The 5’ adaptor sequences are complimentary to 
attachment sites on the micro reactor beads used in both ePCR as well as 
attachment to the surface of the flow cell for immobilization. The 3’ sequence 
serves as a complimentary primer site for the amplification steps; the ligation site 
for sequencing and also this is where the oligo-barcode is inserted if the use of 
multiplexing is desired.  The template with the adaptors ligated is then mixed with 
PCR reagents in an aqueous solution that is suspended and stabilized within an oil 
emulsification. This entire mixture is then massively and clonally amplified in a 
large volume thermocycler. After amplification, the amplified template still attached 
to the micro reactor bead is then deposited onto a flow cell for subsequent on-
instrument sequencing. One obvious advantage of this type of off-instrument 
amplification is that it is possible to evaluate and enumerate the general efficacy of 
the amplification step and possibly discarding or halting insufficient amplifications, 
prior to loading the sample on instrument for a lengthy and expensive sequencing 
run.  
The chemical reactions employed by the SOLiD sequencing protocol are very 
different than the other major NGS platforms. First, the amplified libraries are 
deposited onto the flow cell, much like a gel, they are injected into well (or lanes) 
within the flow cell. Once loaded, a labeled primer in first annealed to the 
complimentary adaptor sequence at the 3’-end of the immobilized library DNA. 
Before any sequencing reactions take place, the fluorescence is measured and 
imaged producing a reference map for optical imaging and quality assessment of 
the following sequencing protocol. After the image index has be made, the 
fluorescent primers are stripped and a new set of non-labeled primers are 
annealed to the template in reverse orientation which presents a phosphate group 
at the 3’-end to which dye-coupled octamer probes are then ligated to, in contrast 
to the polymerase-mediated extension favored by both of the other major NGS 
platforms. The octamer probes that are used consist of a two base specific 
sequence followed by six degenerative nonamers (N) with one of four fluorescent 
labels affixed. There are sixteen possible combinations of the two-base specific 
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probes (four bases x four dyes), which, in the presence of ligase, are allowed to 
compete with each other to anneal at the phosphate group of primer based on 
complimentary sequence. The optical signal of the two-base specific probes are 
then imaged and then the dye-labeled nonamers portion of the probe is cleaved 
and a phosphate group is regenerated at the 5’ end of the newly extended primer 
sequence. This is called a cycle and it is repeated ten times before complete 
cleavage of the initial primer sequence is cleaved off and washed. A new round of 
sequencing commences when a new primer, off-set by one base, is again 
annealed and the whole process is repeated for ten more cycles (Figure 315). This 
continues through five sequencing primers (which takes about six days), 
generating billions of fifty-base pair reads. Because the primer is extended each 
cycle by the ligation of a two-base probe, and offset by one base through each 
successive round of sequencing, each base is independently interrogated and 
effectively sequenced twice. The result is a company reported 99.94% base call 
accuracy when sequence data are correctly de-convoluted in color space, which 
represents the highest call accuracy of the major NGS platforms. Subsequent 
studies seem to concur and indicate that the SOLiD platform does not appear to 
show the same G+C bias as the Illumina system in heavily GC-rich templates28. In 
addition, paired-end sequencing is possible on the SOLiD platform without the 
need to re-amplify the template, as in the case of the Illumina method. To 
sequence the ‘other; end of the library fragment an additional set of primers are 
simply annealed to adaptor sequence at the opposite of the fragment and the 
entire sequencing process is then repeated. The SOLiD system has a similar 
overall output (Gb) per full instrument run to that of the Illumina, but generates 
about twice the amount of reads (~2.6 Billion) to achieve this. There are some 
obvious advantages of this short read system over the Illumina system. For 
example, because the systems routinely generates deeper sequence output it is 
ideally suited to interrogate small RNA libraries and whole transcriptome libraries 
where increased read length is less critical, while the amount of reads becomes 
more critical. The increase in accuracy due to the two-base encoding also 
becomes an important factor with the smaller read length in SOLiD. In addition, the 
SOLiD chemistry controls for out-of-phase reads by capping them to block 
extension. Another advantage SOLiD has over the Illumina platform is the run 
cost, especially for paired-end analysis. Because the libraries are generated off-
instrument and only once, the amount of template to be sequenced can be tightly 
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controlled for both quality and amount, which also makes a multiplexing analysis 
much more efficient. 
There are also some disadvantages of the SOLiD short read platform versus the 
Illumina system. The Illumina instrumentation provides much better ‘walk-away’ 
capability and faster run times. In addition, the library preparation for the Illumina 
system is significantly easier compared to the SOLiD or GS FLX platforms. The 
longer read lengths of the Illumina Genome Analyzer make it more ideally suited to 
whole large genome re-sequencing and large directed re-sequencing projects, 
while the SOLiD is better at aimed at projects like transcriptome analysis due to 
the greater number of sequence tags generate. 
The next steps in NGS technology are poised to address two major areas of 
weakness for the three aforementioned platforms. The first area, Life Technologies 
and Illumina, both, have developed bench top sequencers focused on 
improvement of scalability, both in terms of speed and sample size –which also 
collaterally affects the price. These new instruments, The Personal Genome 
Machine (PGM) and the MiSeq, from Ion Torrent/Life Technologies and Illumina 
respectively, are making NGS accessible to most academic and private genomics 
facilities all over the world. With significant increases in speed and reduction of 
costs, these new instruments are bridging the gap between clinical and research 
applications for sequencing-based testing.  Accuracy, however, remains a critical 
issue that needs further development before NGS replaces Sanger-based 
sequencing for most clinical sequencing facilities. The other future area of focus 
remains on the weakness of current NGS technology to interrogate very low input 
sources and for the need to build complex libraries, which are heavily reliant on 
several rounds of enzymatic reactions and harsh selection and clean-up 
methods29. The goal is to study cellular activity with native resolution at the 
molecular level. Pacific Biosciences has developed a platform that is capable of 
true single molecule sequencing, with no amplication of the input needed and can 
detect base modifications with read lengths averaging nearly one Kilobase. 
Reliability, high error rates, and cost are currently a monumental problem with the 
single-molecule real-time technology (SMRT) from Pacific Life Sciences for most 
facilities, but the ability to detect base modifications and the ability to sequence 
highly repetitive genomic regions with great alignment accuracy due to the long 
read lengths give this platform a trajectory for use in epigenetic studies where 
base modifications are routinely found in heavily repeated elements within many 
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complex genomes. Another technology on the horizon, which also addresses 
some of the same NGS constraints as the SMRT platform, is nanopore 
technology. A nanopore is, essentially, a nano-scale hole, which may consist of: 1) 
a biological molecule, such as a protein that forms a small pore in membrane lipid-
bilayer 2) synthetic molecule such as graphene or a silicon derivative 3) a 
combination of both biological and synthetic. Essentially, a single strand of DNA, 
RNA or Protein can be passed through the nanopore with a current and sensors 
detect changes in the current’s profile and can determine differences in bases, 
including single base modifications. Long reads are also feasible, but difficulty 
reading homopolymers may be an issue as with the PGM platform30,31.  
It is becoming increasing clear that NGS platforms currently available and on the 
horizon are destined to become highly specialized instruments filling niche roles in 
genomics that can take advantage of a platform’s respective strengths, while 
essentially minimizing areas where they are less advantageous. 
 
Colon and Rectal Cancers  
 
The distinction between colon and rectal cancers is largely an anatomical 
distinction, at least at this point, and they are commonly referred to as a single 
disease in humans, colorectal carcinoma (CRC). The disease progresses from 
non-malignant polyps or lesions, which vary significantly in histomorphological 
characteristics. CRC has a large malignancy-related mortality rate in industrialized 
countries, annually killing more than half a million people worldwide, with a 5-year 
survival rate at approximately fifty percent. Metastasis to other major organs, such 
as the liver and lungs is often swift and is the primary cause of death, occurring in 
nearly twenty-five percent of patients at presentation32,33. The disease is a highly 
complex one, and yet, despite a large number of recent genome-wide sequencing 
studies that have revealed several genetic discoveries in CRC, to a large degree, 
the disease is not well characterized. A fully integrated view of the disease linking 
genetic alterations, epigenetic and transcriptional regulation at the coding and non-
coding levels remains elusive for CRC.   
 
Classifications of CRC 
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Because of the heterogenic nature of the disease, several histological and 
morphological CRC tumor variations are distinguishable and are indicative of a 
complex genotype-to-phenotype relationship in CRC tumorigenesis. However, the 
molecular causes and effects of such variability in these tumors need better 
understanding before effective therapeutic treatment options can be developed.  
Currently, the histological hierarchy, as defined by the World Health Organization 
(WHO) for CRC, stratifies tumors into adenocarcinoma or non-glandular variant 
classes, both driven by hereditary and somatic genetic factors, as well as clonal 
selection under lifestyle and environmental pressures34.  The molecular 
classifications of tumorigenesis are either hereditary or non-hereditary, but much 
of the body of work of CRC studies focuses on hereditary tumorigenesis, due to 
the highly variable nature of CRC tumors, however, there are some pervasive 
molecular characteristics which span throughout sporadic CRCs and even some 
inherited cases. Most notable, is the prominent role of APC gene in sporadic 
adeno-carcinomas. Between 70%-80% of all sporadic CRCs exhibit an inactivating 
mutation in the APC gene, and nearly all mutations result in a truncated form of 
the APC-protein. Familial adenomatous polyposis and hereditary nonpolyposis 
colon cancers (HNPCC, also known as Lynch Syndrome) account for the vast 
majority of hereditary CRCs, which comprise nearly ten to fifteen percent of all 
CRC cases woldwide35. Current molecular classifications segregate both 
hereditary and sporadic tumors into three main categories, genomic instability 
(GIN), serrated neoplasias, and a newly anointed class for molecular 
characteristics that do not completely fit the two aforementioned classes.  
 
Genomic instability is subdivided into three principle subclasses. The most 
common type of GIN, is chromosomal instability (CIN) which include chromosomal 
displacement or rearrangements, copy-number alterations, as well as mutations. 
For example, loss or partial loss of the 18q chromosomal region deleterious for 
genes such as SMAD2, SMAD4, or DCC, is found in up to 70% of primary CRCs, 
is a common molecular profile of CIN-related tumors36. Other characteristic 
molecular features of CIN-associated carcinomas are mutations in APC and KRAS 
genes. Although, CIN-related molecular lesions are known to be found in 
dysplastic foci, it has not been clearly demonstrated that CIN is responsible for 
malignancy or whether it simply a result. However, it believed that CIN acts as a 
molecular driver and promoter of neoplasia, but a single, putative driving CIN 
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event has yet to be identified37,38. Unfortunately, CIN-implicated carcinomas do not 
present an identifiable characteristic histomorphological profile, but they can be 
differentiated on the basis of tumor grade, necrosis, and the presence of 
extracellular mucin. 
Another sub-class of GIN-related carcinomas is microsatellite instable (MSI). 
Microsatellites are genomic regions where short stretches of DNA sequence (or a 
single nucleotide) are repeated. There are hundreds of thousands of 
microsatellites scattered throughout the human genome. During DNA replication, 
mutations sometimes occur in some microsatellites causing misalignment of their 
repetitive subunits, which results in truncated or elongated strands, which are 
usually repaired by DNA mismatch-repair proteins. However, in tumors with a 
deficiency of these proteins, the repair mechanism often fails, or is incomplete. In 
CRC’s with MSI, more than half of all microsatellites have mutations, 
consequently, making microsatellite instability an effective and straightforward 
marker of mismatch-repair deficiency32,39. It occurs in nearly all cases of HNPCC 
(or Lynch Syndrome) and is present in ~15% of sporadic cases of CRC35,40. MSI 
generally occurs when both alleles are knocked out by somatic inactivation or 
where there is an inherited germline mutation in one allele with an additional 
somatic inactivation of the other, but without any chromosomal abnormalities41. 
The normal mismatch repair function, which typically produces truncated alleles is 
either knocked out or is aberrant in MSI tumors. These types of tumors are not 
generally associated with KRAS or TP53 gene mutations, but the BRAF status is 
considered a prognostic indicator with survival greatly improved in patients with 
MSI and BRAF intact42. From a pathology standpoint, MSI CRC specimens are 
often, but not always, heavily mucinous, littered with lymphocytes, and are 
inflamed at the tumor periphery which make them difficult to differentiate under a 
microscope41,42. 
The final subclass of GIN CRC’s is the CpG island methylator phenotype (CIMP). 
The CIMP class contains islands of CpG rich repeated elements, often found 
within or near promoter regions. In carcinogenesis, hyper-methylation of CpG 
islands is tantamount to transcriptional inactivation of genes with cell-cycle 
regulatory functions, such as tumor suppression, DNA mismatch repair, or 
apoptosis43. Typically, the genes that are most often associated with epigenetic 
modification in CIMP are p16, MGMT, and hMLH1. CIMP-classed tumors are 
further stratified based on their molecular profiles. For example, carcinomas with 
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frequent MSI and a dysfunctional BRAF gene are considered CIMP1, while those 
that are microsatellite stable, but exhibit frequent mutations in KRAS are 
considered CIMP2. In addition, microsatellite stable carcinomas where TP53 is 
frequently mutated are generally CIMP(-)44,32. Proximal methylation of the hMLH1 
mismatch repair gene is a common characteristic of CIMP CRCs, with about half 
of all CIMP CRCs being microsatellite stable. In general CIMP CRCs are 
associated with mutations in BRAF and/or BRAF genes and a poor prognosis. 
Similar to the MSI class of tumors, CIMP carcinomas are difficult to differentiate on 
a histomorphological basis and despite methylation of the hMLH1 promoter region, 
a characteristic phenotype is currently not well defined45.  
 
The serrated pathway is the next major class of CRCs with distinctive molecular 
and histomorphological characteristics. Tumors associated with the serrated 
neoplasia pathway are often characterized by an early promoting mutation in the 
BRAF gene. The subsequent increase of function of BRAF blocks or limits the 
activity in the apoptosis pathway in serrated polyps through an over-production of 
a serinethreonine kinase46,37.  The histomorphological and molecular phenotype of 
serrated polyps or adenomas varies considerably, but are generally separated into 
two classes, sessile and traditional serrated adenomas/polyps. Sessile serrated 
adenomas/polyps (SSA/P) make up about 20% of all the serrated polyps, and 
have elongated L-shaped or anchor-shaped crypts and a large proliferative zone. 
SSA/Ps are typically found in the right hemicolon and are associated with 
progression to invasive adenocarcinomas47,36.  
Traditional serrated adenomas (TSA) generally have conventional adenoma 
characteristics with a serrated architecture, but they can also possess large 
column-like cell walls with a serrated architecture. They differ from SSA/Ps in that 
they exhibit left-sided localization, KRAS status (mutated in about 25%), and an 
increase in methylation frequency (notably, MLH1 is not methylated). 
Unfortunately a strong correlation of phenotype and genotype in not well defined in 
the serrated neoplasia pathway, but these polyps are highly malignant and are 
classed molecularly by the exhibition of MSI, BRAF or KRAS mutations and 
CIMP47,48. 
 
The CRCs which have newly characterized molecular mechanisms and pathways 
that can not be segregated into GIN or serrated neoplasias, have recently been 
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placed into a separate class of molecularly distinct carcinomas called additive 
molecular carcinomas36,49. These recent molecular findings include genetic and 
epigenetic alterations, but also non-coding RNA deregulation. These include, but 
are not limited to: histone modifications, loss of function for genes such as TP53, 
TGF-beta and APC with tumor suppressive roles; activation of the oncogenic RAS-
RAFMAPK and P13K-Akt signaling pathways. Alterations in the non-coding 
transcripts of carcinogenesis are of particular interest, as CRCs have been 
described with deregulated microRNAs associated with both tumor suppressive 
and oncogenic activity. For example, down regulation of miR-143 and miR-145 
and up-regulation miR-17-5, miR-31, and miR-183 have been identified in the 
carcinogenesis of colorectal lesions and polyps37,49,50. Molecular data 
characterizing the network of coding and non-coding RNAs and other genetic 
alterations are growing at a rapid pace with the technological developments in the 
capability to study genomics and these data should help to further stratify CRC 
classifications and to help clarify the current heterogeneity in histomorphological 
features.  
 
Current Strategies in the Treatment of Colorectal Cancer 
 
The most effective method for the diagnosis and predicting prognosis in the 
majority of patients diagnosed with colorectal adenocarcinomas continues to be 
the staging system from the American Joint Committee on Cancer (AJCC) or more 
commonly referred to as the TNM staging system32. The TMN is an acronym for 
the three criteria used in the system. The (T) refers to the growth extent of the 
primary tumor; (N) refers to the nearby spread to regional lymph nodes; (M) refers 
to the spread of tumors cells to distant organs and tissues, called metastasis. 
Based on the pathology of these criteria, tumors are grouped into four stages (i-iv), 
which in some cases can be further differentiated into sub-groups34. Stage I 
represents primary tumor growth with no spread to adjacent tissue or lymph 
nodes; stage II tumor growth has spread to the outer walls of the colon or rectum 
but has not penetrated them; stage III tumor growth has spread to nearby lymph 
nodes and/or adjacent fatty tissues, but not major organs; stage IV is the most 
serious stage as tumor growth has spread to distant organs34,51.  Tumor biopsies 
are often graded on their histomorphological resemblance to normal colon or rectal 
cells/tissue as being “low grade” (similar to normal) or “high grade” (abnormal). 
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Low-grade tumors tend to progress slower than high-grade tumors, with better a 
prognosis. Grade is often considered with prescribed post-surgical adjuvant 
treatment with chemotherapeutics34. Patient response to chemotherapeutics and 
tumor classification (grade and stage), remain the prognostic gold standard 
directly correlated to patient outcomes. Most patients diagnosed with stage I-III, 
low-grade CRCs are usual treated with surgical options alone or sometimes in 
combinatorial treatment with chemotherapy and have been shown to have a five-
year survival rate of 93.2% for stage I, 82.5% for stage II, and 59.5% for stage III 
patients. These survival rates are in stark contrast to those patients diagnosed 
with stage IV carcinomas, which typically have higher-grade tumors and a five-
year survival of 8.1%32-34. For those patients who are at risk for developing 
metastasis or primary reoccurrence (stages II, III) or those that have been 
diagnosed with metastatic tumors (stage IV), adjuvant chemotherapy is typically 
used as the post surgical treatment strategy. However, despite the widespread 
use of chemotherapeutics to treat late stage carcinomas, the molecular 
mechanisms that determine clinical response in patients remains unclear. As a 
result, significant portions of those patients who are prescribed chemotherapy 
derive no tangible benefit from this treatment and are potentially at greater risk of 
toxic over treatment. In addition to problems associated with toxicity, there is a 
substantial financial burden on the health care system for continued ineffective 
treatment regiments51-53. It is critical to gain a better understanding of the 
underlying molecular mechanisms involved in both carcinogenesis and patient 
response. It is also essential to identify better prognostic markers so that we can 
better segregate patients into those who are most likely to benefit from current 
adjuvant therapy and to design more effective regiments in the future for those 
who do not benefit from current strategies. These are the primary goals for the 
continued and future clinical management of patients diagnosed with CRC. 
 
Molecular Biomarkers in CRC 
 
Although the TNM staging system is the most effective predictive tool in the clinical 
management of CRC, the use of the TNM system alone is not very effective at 
determining the efficacy of the adjuvant therapies. Recent developments in 
genomics and the ability to perform genome-wide association studies with next-
generation sequencing have provided a critical boost to molecular data with 
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respect to clinical outcomes and carcinogenesis in CRC. The use of molecular 
markers is gaining popularity as an effective tool to predict clinical response in 
patients with various treatment regiments. These markers have also provided the 
possibility for future targets of therapeutic intervention. Several potential 
biomarkers have been described; yet only mutations in KRAS have been largely 
used as clinical predictors in the treatment of CRC (Table 159). This is largely 
because most of the biomarkers studied thus far have failed to definitively produce 
molecular signatures that validate their respective clinical outcomes54.  
In other cancers, such as, certain leukemias and breast cancers molecular gene 
expression profiles have either been approved or are in the process of approval by 
the US Food and Drug Administration (FDA) as decision-making tools in support of 
particular cancer treatment options54.  
The use of the APC gene which, when deactivated, disrupts the APC/WNT 
pathway, looks promising as a potential early marker of carcinogenesis in 
adenomas, as inactivation usually occurs in the normal epithelium. Additionally, 
the status of TP53 and TGF-β/SMAD4 have shown promise as biomarkers, 
because the loss of either or both has been implicated in the enabling of clonal 
expansion of tumor cells in the invasive adenocarcinomas 55,56.  
The members of the Ras family of genes are group of three proteins that operate 
downstream of several receptor tyrosine kinase (RTK) growth factors (e.g., 
epidermal growth factor receptors (EGFR); mitogen-activated protein kinase 
(MAPK) and PI3K pathways) and ultimately impose regulation of cellular growth in 
normal cells. They have been implicated in many cancers, including colorectal 
cancer where nearly 40% of adenocarcinomas have been shown to have somatic 
mutations in KRAS54. However, mutations in KRAS are also commonly found in 
polyps and adenomas that rarely progress to malignancy so KRAS is not a marker 
of requirement in the progression from colorectal adenoma to carcinoma, but it 
clearly helps drive the development of advanced CRCs and is associated with 
poor prognosis of the disease57. 
Mutations in the BRAF gene are closely associated with an altered form of the 
typical adenoma-carcinoma progression known as CIMP where the DNA is highly 
methylated. Therefore, it has significant potential to be used a diagnostic 
classification marker, however, it is also associated with poor outcomes and so it 
also has potential as an important prognostic indicator of survival58.  
To a lesser degree, mutations in TP53, CMYC, PTEN, AKT, PIK3CA, SOX9 and 
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SMAD2/4 genes are found in small sub-classes of CRC and are potentially 
prognostic, but further clinical analysis is necessary before their worth as 
prognostic biomarkers can be determined60 (Table 159). 
To date the majority of gene expression sequencing studies on CRC have focused 
primarily on coding mRNA expression, and thus many non-coding regulatory 
elements, such as microRNAs that may have significant prognostic value as 
biomarkers may have been overlooked. However several microRNAs have been 
described seemingly with significant potential as biomarkers in various stages of 
carcinogenesis in colorectal cancer. For example, miR-17-92, miR-135, and miR-
145 have been implicated in early progression from normal epithelial tissue to the 
formation of adenomas. In addition, let7, miR-18a, miR-21, miR-126, miR-143, 
miR-34a-c, and miR-483-3p61 all seem to play an important role in the progression 
of adenoma to carcinoma, but their relative prognostic values need further clinical 
study59 (Figure 459). 
As the study of potential CRC biomarkers and expression profiles expands and as 
significant improvements are made into the design and clinical patient data 
collection, molecular biomarkers will become a routine and an effective predictive 
method to support decisions on the future clinical management of CRC.  
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METHODOLOGIES 
 
Small RNA library generation and sequencing. 
 
Written informed consent was obtained for all patients, and the institutional review 
board (IRB) approved the study. Serial cryosections were obtained from all 
tumors. The first and last cryosections of each series were used to verify tumor 
cell content. Samples were only included in this study if the tumor cell content was 
>70 %. Cryosections not used for histological analysis were transferred to TRIzol, 
and total RNA was extracted using the miRNEASY kit (Qiagen) according to the 
manufacturer’s recommendations. For all samples, 2 g of extracted total cellular 
RNA was size selected by gel electrophoresis and excision to preserve to <40nt 
RNA faction for subsequent library preperation. Libraries for deep sequencing 
were prepared from the size-selected total RNA according to the manufacturer’s 
protocol [SREK (small RNA expression Kit), Life Technologies, Foster City, CA.], 
with one notable exception: during the library amplification, only 12 rounds of PCR 
were used as opposed to the 15 that are called in the protocol. The reason for this 
was to reduce the amplification noise and adaptor amplification, as the majority of 
target lengths were atypically small ~17-25bp for PCR templates. Library integrity 
was monitored using a Bioanalyzer (Agilent). Template bead preparation, 
emulsion PCR and deposition steps were performed according to the standard 
protocol, and slides were analyzed on a SOLiD system Version 3.0 (Applied 
Biosystems). 
 
Sequence processing and mapping  
 
Mapping of SOLiD reads was performed using both the small RNA pipeline (Life 
Technologies) and PASS. The small RNA pipeline and PASS were used to extract 
counts and extensions of miRNA in small RNA reads, from 18 nucleotides in 
length. When matching to either miRNome (precursor sequences from miRBase) 
we recorded only perfect matches. When we aligned the short RNA reads to the 
whole genome, we recorded alignments with up to one mismatch. Only reads with 
at least 3 sequenced reads per sample were inputted in the SQL database. Raw 
digital expression values (read counts) were obtained by summing the number of 
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reads that mapped to one of the reference databases, human genome hg19, 
miRBase release 16.0, viral or bacterial genomic sequences from NCBI. The 
confidence in the correct assignment of short reads to miRNAs or other genomic 
locations was increased by discarding reads mapping to more than 4 loci (as 
almost all known human miRNAs are equally or less repetitive). For merging of 
short RNA reads into short RNA contigs (shortigs), we considered each mapped 
read with at least 3 counts in each sample, either normal or cancer, maintaining 
the strand. We merged into a single transcriptional unit all the reads within a 
distance of less than 100 nucleotides. We also assigned to each shortig a score 
which was the sum of the distinct reads (not the counts of reads) for each 
sample/patient (i.e. 1 read in 5 patients = 5, 3 distinct reads in 5 patients = 15. 
Thus this score does not take in account transcriptional activity (i.e. counts of 
reads per sequence per sample). We finally retained the 270,216 merged shortigs 
with consistent transcription by using a score threshold of 5. 
To quantify the short RNA reads we used two modifications of RPKM scaling85, 
based on the read count of each analyzed sample. For short RNA reads , the 
index consisted of the read count divided to the number of (millions of) mapped 
miRNA reads in the sample (RPMM). As the length of the short reads was almost 
constant, we did not use here the division by length in kilobase. Quantiles 
normalization was used after RPMM scaling. Thresholding was at equal to, or less 
than, 5 RPMM. Allowed percent absent values for each short sequence, were 
85%. Datasets with less than 1 million matched reads were not analyzed further. 
For the quantification of short RNA contigs, the length in kilobases was used to 
standardize the reads per million matched miRNAs, thus defining RPKMM. 
RPKMM was used in place of RPKM, because we used size selected RNA as 
starting material, rather than un-fractionated RNA. 
 
Additional miRNA detection techniques 
 
Total RNA (20ng) was reverse transcribed using the RT stem–loop primer system 
(Applied Biosystems), enabling miRNA-specific cDNA synthesis. Subsequent RT-
PCR with Exiqon LNA kit was also used.  
Northern blot analysis was performed as previously described66.  
NanoString assays were performed as described by the manufacturer. 
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Statistical analysis 
 
R (http://www.r-project.org) and BRB Array tools were used for statistical and 
clustering analysis. Filtering of expression tables was performed as follows. Reads 
or contigs were not analyzed further when less than 20% of the expression data 
had at least a 1.5-fold change in either direction from the median value and when 
percent of data missing or filtered out exceeds 50%. We decided to use quantiles 
normalization on the short RNA reads, after RPMM standardization, as all the 
evaluated parameters indicated a clear improvement. 2969 short RNA reads were 
differentially expressed in colon adenocarcinoma (p-value< 0.05), with a global p-
value of: 0.007. The shortigs identified by at least 1 significant short read were 
further studied by summing the RPMMs of all the spanning short reads. For each 
shortig RPKMM were obtained (reads per kilobase per million miRNAs). Paired t-
test was performed on the selected RNA shortigs (same filtering conditions as for 
short RNA reads). Classification prediction was performed using different models 
(diagonal linear discriminant, nearest neighbors, and nearest centroids) and 
incorporated non-coding RNA shortigs that were differentially expressed at the 
0.05 significance level, as assessed by the random variance t-test. The 
misclassification error was estimated for each model by using leave-one-out cross-
validation86. 
 
RESULTS AND DISCUSSION 
 
Small RNAs are regulatory class of evolutionarily conserved, non-coding RNAs  
(ncRNAs) that are involved in the regulation of gene expression. Alterations in the 
expression these small non-coding elements have been shown over the past 
several years to contribute to the disruption of messenger RNA (mRNA) 
expression and ultimately to the pathogenesis of most, if not all, human 
malignancies. These alterations can be caused by various mechanisms, including 
deletions, amplifications or mutations involving miRNA loci, epigenetic silencing or 
the de-regulation of transcription factors that target specific miRNAs65. Some 
miRNAs have very strong association with cancer66. Among them, miR-21 is over-
expressed in most tumor types67. Over-expression of miR-21 in mouse leads to a 
pre-B malignant lymphoid-like phenotype, demonstrating that mir-21 is a genuine 
oncogene68. When miR-21 is inactivated, the tumors regress completely in a few 
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days, partly as a result of apoptosis. These results demonstrate that tumors can 
become addicted to onco-miRs. On the other hand some miRNAs are strongly 
down-regulated in cancer, such for example miR-14569,70 that can regulate the 
quiescent versus proliferative phenotype of smooth muscle cells71. Consequently, 
there are some important applications of miRNAs with clinical relevance. First, 
miRNAs have been proposed as biomarkers in early diagnosis of cancer by non-
invasive techniques. Second, because malignant cells show dependence on 
miRNAs, which in turn control, or are controlled by, multiple protein-coding cancer 
genes, these small molecules provide opportunities for the development of RNA-
based therapies. The advantage of a miRNA approach is based on its ability to 
concurrently target multiple effectors involved in cell differentiation, proliferation 
and survival72.  
Our goal was that of systematically sequence all short RNAs in colon 
adenocarcinoma, including miRNAs, to assess the absolute expression and 
diagnostic significance of the expanding classes of non-coding RNAs. First, to test 
our procedure, we used the short RNA reads to measure only miRNAs, as 
described in miRBase73. We used two different methods, the Small RNA Pipeline 
(SRP)74 and PASS75. The algorithms were both implemented in a pipeline which 
funneled all the alignments from the patient cohorts into a SQL database. miRNAs 
were identified by next generation sequencing with perfect match to the miRBase 
precursor sequences. Table 2 shows the miRNAs which discriminate between 
colon adenocarcinoma and normal tissues (p-values <0.01). Fold change was the 
ratio of geometric means of RPMM (reads per million of matched miRNAs) in 
adenocarcinoma vs. normal paired samples from the same patient. Mature and 
isomiRNA forms (i.e. different mature reads for the same miRNA) were annotated 
according to miRBase 16. Only the isomiRNAs detected by both the SRP and the 
PASS algorithms are listed in Table 2. The miRNAs identified with the two 
methods were essentially overlapping, albeit PASS was more sensitive, with a 
gain of 53% in the number of significant iso-miRNAs (393 in PASS vs. 256 in 
SRP). The results for the individual pipelines are reported in Table 3. There was a 
very good correlation between the miRNA counts using the two algorithms (Figure 
8, adjusted R square = 0.96). When the ends of iso-miRNAs used were plotted 
along the precursor sequences, it was apparent that the seed region in the 
isomiRNAs was either entirely or partially identical to that of the canonical mature 
form. Figure 9 and figure 10 both show the respective ends’ usage graphs for miR-
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21 and miR-145. These iso-miRNAs were therefore expected to share the same 
biological activity of the respective mature forms. We then plotted for each miRNA 
the cumulative RNA counts along the precursor sequence. The plots for 397 
distinct miRNA are available online (http://aqua.unife.it/miRNAplots). Among them 
we detected discrepancies between 150 miRNAs and their miRBase definitions. 
The miRNAs for which discrepancies were present are listed in Table 4 and were 
particularly frequent among the most recently discovered miRNAs. In detail, 9 
miRNAs were expressed mainly from the opposite strand of the precursor, 20 
were identified by different mature form coordinates, and 19 putative miRNAs 
revealed an aberrant expression plot much unlike that of a classical miRNA. 
Further, we measured higher expression of the star over the mature form in 33 
miRNAs.  
A major aim in our work was to identify novel non-coding RNAs, beyond known 
miRNAs, having a diagnostic value in colorectal adenocarcinoma. We thus aligned 
all the sequenced short RNAs to the whole human genome, using the PASS 
pipeline, and without a priori distinguishing miRNAs from other genes. In order to 
accurately measure the expression levels and to correctly map short RNAs we 
used only perfect matches to the human genome. The trials we did allowing even 
only 1 mismatch in fact resulted in a large number of mapping ambiguities. Perfect 
matching would in principle be a problem for the determination of SNPs, but we 
disregarded this, because we were not concerned with presence of SNPs at this 
time, due to the very short size of the reads it is very difficult to very SNPs 
occurring at the level of RNA processing. When only perfect matches were 
considered in the alignments of the colon samples, a total of 477,595 distinct short 
reads were mapped. If strand was not considered, we identified 476,882 distinct 
loci; i.e. less than 1000 loci were transcribed on both strands. Perfect match 
yielded about 66% of mapped reads, while allowing for 1 mismatch the aligned 
reads were more than 99%. Again, we decided not to use the alignments with one 
mismatch because, even if mapping to just one locus, they vastly increased the 
number of loci and decreased the statistical significance of data, hinting at an 
increase in noise, rather than information. Among all the distinct RNA reads we 
needed to identify those produced by defined and consistent transcriptional units, 
and remove lone RNA molecules detected only in very few samples or at very low 
level. To attain this goal, we used all the mapped short RNA reads in our samples 
to define a genome wide map of short RNA loci with consistent transcriptional 
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activity. We did so by preserving RNA transcription strands. By merging the reads 
with close spatial contiguity, we identified 270,216 short RNA contigs (hereafter 
named shortigs) with consistent transcriptional activity in cancer and normal 
samples. All miRNAs expressed in colon were present among these 270K shortigs 
(a Genome Browser custom track with all the genomic coordinates for the 270K 
shortigs can be obtained at http://aqua.unife.it/ShortigShapes). About 42% of the 
shortigs were found to be overlapping to non annotated ESTs, 4% mapped to 
repeats and only 12% mapped to highly conserved sequences 
(phastConsElements46way UCSC table). Nevertheless when the these 
sequences were compared to ESTs from other organisms (XenoEST table), a 
large portion (91%) found an homologue, showing that most of the shortigs are 
transcribed in some organisms. The shortigs were annotated according to UCSC 
Genome Browser. Since it was possible that for short RNAs the traditional gene 
models were too conservative, we used the Gencode76 gene model alongside the 
established UCSC annotation system. A graphical representation of a shortig is 
shown for the miR-17-92 cluster (Figure 5A). 
We finally proceeded to identify the RNA shortigs with diagnostic value in colon 
carcinoma. Reads per kilobase per million miRNAs were used to measure 
expression of the shortigs. T-test and permutations were performed to assess p-
values and false detection rates. Overall, 129 RNA shortigs were differentially 
expressed in colon carcinoma, with p-values <0.05 in paired t test (Table 3). This 
non-coding RNA signature was also efficient in predicting cancer and normal colon 
samples. The leave-one-out cross-validation method was used to compute the 
misclassification rate: > 90% with diagonal linear discriminate analysis, nearest 
neighbors or nearest centroids (Table 5). Fifty-six of the shortigs (43.4%) 
coincided with miRNA precursors or clusters (Figure 5B). Among the remaining 
RNAs, 52% were novel RNAs with unknown function (45 are intragenic and 22 are 
intergenic). 59 RNA contigs were up-regulated and 70 down-regulated in colon 
adenocarcinoma. The respective ratio in miRNAs was 19 vs. 37, with a slight 
excess of miRNA down-regulation in comparison to the non-miRNA counterpart. 
We performed detailed manual inspection for the genome location of all 
differentially expressed novel RNAs. Four additional annotated shortigs were thus 
identified: a couple of tRNA-like genes (chr11:65273440-65273625+ at 11q13.1 
and chr10:69524258-69524366+ at 10q21.3), a novel snoRNA (SNORD19B, at 
3p21.1) and a piRNA (piR-51810 at 8q13.2). Seven novel RNA genes were 
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located very close (<1 kb) to regions of chromatin modification as reported by the 
Encode77 tracks. Among the shortigs located within introns of coding genes, there 
was an equal distribution between sense and antisense orientations with respect 
to the host gene. The expression range, subdivided by RNA classes, was highest 
for miRNAs, with a 2 logs difference in the maximal values (Figure 5C). The 
steepness of the curves in cancer and normal samples were similar within the 
different RNA classes, with the exception of the small snoRNAs/piRNA class, 
showing a noticeable bump in cancer. The tree representing the cluster analysis of 
the short RNA contigs is shown in Figure 6. For each of the 129 diagnostic 
shortigs we generated an expression plot with cumulative RPKMM along the 
contig. Plots for two miRNAs, a piRNA and a snoRNA are shown in Figure 7. It is 
interesting to note that the peak of the snoRNA within the GNL3 host gene was 
larger than the individual sequencing reads. All the shortig plots are available 
online at http://aqua.unife.it/ShortigShapes. Some miRNAs were sporadically, or 
not at all, reported in colon cancer, like up-regulated miR-135b, miR-503, miR-
18378, miR-182 and down-regulated miR-129, miR-137b, miR-9, miR-138, miR-
218, were present in the short RNA signature. Expression of p53 responsive miR-
21579, implicated in cell-cycle arrest, was also decreased in colon 
adenocarcinoma. Many of these miRNAs had lower RPKMM in comparison to the 
most prominent miRNAs in the colon adenocarcinoma signature, like miR-2180 and 
miR-14581 (Table 2). It is possible that low abundance miRNAs might have often 
been discriminated against in the studies performed with less sensitive or robust 
detection techniques. The abundant miR-29a was over-expressed in CRC, while 
the related low abundance miR-29b was down-regulated (Table 6). When we 
validated the expression of these two miRNAs, with RT-PCR and Northern blot the 
signal of miR-29b (low RPKMM) was confounded with that of miR-29a (high 
RPKMM), and thus erroneously called as up-regulated. Only by using LNA-based 
PCR and Nanostring we could validate the down-regulation of miR-29b. The 
summary of the validation of a set of miRNAs by using different technical platforms 
pointed out to next-generation sequencing as the most robust detection method. In 
order to substantiate the relevance of these non-coding RNAs in cancer we 
studied their presence in chromosomal areas associated to copy number 
variations. We used the comparative genomic hybridization (CGH) Progenetix 
database82 to identify regions of amplification or deletion in a large number of 
cancer samples. We called an area as amplified or deleted, if there was a 
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corresponding 3-fold change in the number of abnormalities detected over a 
cytoband. A number of amplifications were associated to over-expressed RNA 
shortigs (Table 7). In particular, miR-135b, miR-183, miR-182, miR-21, miR-29a 
and miR-25 were in frequently amplified regions (cytobands with number of 
amplified cases over number of deleted cases > 3). RNA shortigs which were also 
amplified, included SNORD12, SNORD54, SNORD78, SNORD123 and other 
novel short RNAs. 
 
CONCLUSION 
 
We used short RNA sequences in the range between 18 and 35 nucleotides to de 
novo assemble non-coding RNA genes and measure their activity in colon 
adenocarcinoma and normal cells. The technique we used covered contiguous 
stretch of RNAs, and allowed the identification of miRNA precursors, or even 
primary RNAs from miRNA cluster, like the miR-17-92 locus on chromosome 
1383,84. The quantification of short RNAs was also used to derive a transcriptional 
profile along each RNA contig or shortig. This allowed us to map the mature and 
star forms along each human miRNA precursor. We detected a number of 
expressed isoforms for each miRNA, but they did not seem to change the 
targeting specificity determinant, the seed region. The slope on the 5’ of mature 
miRNAs was usually steeper than that on the 3’ end. Finally, some of the 
differentially regulated short RNAs are routinely used as normalizers in various 
molecular biology assays due to their seemingly stable and ubiquitous expression, 
which is alarming. For instance, U48, which is often employed as a normalizer in 
PCR and other assays, was noticeably varied in expression between groups. It is 
apparent that such usage might significantly affect the outcome of any genome 
wide assay. The key finding in this study, was that we demonstrated that non-
coding RNA is differentially regulated in colorectal adenocarcinoma, but is not 
limited to mRNAs and miRNAs alone, as previously surmised, but also includes 
deregulation at the snoRNA and piRNA levels as well. These effectors can exert 
key control over vast number of cellular functions, such as alternative splicing and 
gene silencing64. 
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FUTURE DIRECTION 
 
We have obtained an additional 24 paired normal/adenocarcinoma genomic DNA 
and total RNA samples from the National Cancer Institute (NCI) to continue work 
on profiling coding and non-coding RNAs in CRC, as well as targeted DNA re-
sequencing of a cancer-specific mutanome using SureSelect (Agilent 
Technologies) bait library that we have designed which includes genome loci for 
all microRNA primary sequences; exons from all microRNA processing genes (e.g, 
DROSHA, DICER, etc.) and the exons from approximately ~450 cancer-
associated genes. We believe there significant mutations and/or SNPs present in 
these loci that could have both prognostic and diagnostic impact on colorectal 
cancer that either would not be present at the RNA level or would be very difficult 
to find and/or validate at the RNA level. 
In addition, to these, we designed nearly 38,000 small and large non-coding target 
sequences throughout the genome with an emphasis on fragile sites, breakpoints 
and other genomic translocation hotspots. The intention is to use the RNA 
samples for both mRNA and small RNA transcriptome studies to further 
characterize the difference in expression profiles between normal colon and 
adenocarcinomas. The 48 additional samples contain 32 (16-paired) new and 
previously unused samples, while 16 (8-paired) of the 48 samples are the same 
sample we have used in these studies. We intend to both cross validate these 
findings as well increase our statistical significance on the latest miRbase build. 
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LEGENDS 
Figures 
 
Figure 1. Roche 454 GS FLX sequencing. 
Template DNA is fragmented, end-repaired, ligated to adapters, and clonally 
amplified by emulsion PCR. After amplification, the beads are deposited into 
picotiter-plate wells with sequencing enzymes. The picotiter plate functions as a 
flow cell where iterative pyrosequencing is performed. A nucleotide-incorporation 
event results in pyrophosphate (PPi) release and well-localized luminescence. 
APS, adenosine 5_-phosphosulfate. 
 
Figure 2. Illumina Genome Analyzer sequencing. 
Adapter-modified, single-stranded DNA is added to the flow cell and immobilized 
by hybridization. Bridge amplification generates clonally amplified clusters. 
Clusters are denatured and cleaved; sequencing is initiated with addition of primer, 
polymerase (POL) and 4 reversible dye terminators. Post-incorporation 
fluorescence is recorded. The fluorofor and block are removed before the next 
synthesis cycle. 
 
Figure 3. Applied Biosystems SOLiD sequencing by ligation. 
Top: SOLiD color-space coding. Each interrogation probe is an octamer, which 
consists of (3_-to-5_ direction) 2 probe-specific bases followed by 6 degenerate 
bases (nnnzzz) with one of 4 fluorescent labels linked to the 5_ end. The 2 probe-
specific bases consist of one of 16 possible 2-base combinations. Bottom: (A), The 
P1 adapter and template with annealed primer (n) is interrogated by probes 
representing the 16 possible 2-base combinations. In this example, the 2 specific 
bases complementary to the template are AT. (B), After annealing and ligation of 
the probe, fluorescence is recorded before cleavage of the last 3 degenerate 
probe bases. The 5_ end of the cleaved probe is phosphorylated (not shown) 
before the second sequencing step. (C), Annealing and ligation of the next probe. 
(D), Complete extension of primer (n) through the first round consisting of 7 cycles 
of ligation. (E), The product extended from primer (n) is denatured from the 
adapter/template, and the second round of sequencing is performed with primer (n 
_ 1). With the use of progressively offset primers, in this example (n _ 1), adapter 
bases are sequenced, and this known sequence is used in conjunction with the 
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color-space coding for determining the template sequence by de-convolution (see 
Fig. 1 in the online Data Supplement). In this technology, template bases are 
interrogated twice.  
 
Figure 4. The role of microRNAs (miRNAs) in colorectal cancer (CRC) 
pathogenesis. Selected miRNAs that show altered expression in CRCs, along 
with their potential messenger RNA targets, are indicated. The scheme is based 
on the genetic model for colorectal cancer highlighted by Fearon & Vogelstein25. 
Abbreviations: APC, adenomatous polyposis coli; CASP3, caspase 3; CDK4,6, 
cyclindependent kinase 4,6; ECM, extracellular matrix; CTGF, connective tissue 
growth factor; DCC, deleted in colorectal carcinoma; 
EGFR, epidermal growth factor receptor; EMT, epithelial-to-mesenchymal 
transition; ICAMs, intercellular adhesive molecules; MMPs, matrix 
metalloproteinases; mTOR, mammalian target of rapamycin; PDCD4, 
programmed cell death 4; PTEN, phosphatase and tensin homolog; RECK, 
reversion-inducing cysteine-rich protein with kazal motifs; SIRT1, sirtuin 1; 
TGFβRI/II, transforming growth factor βreceptor I/II; TIMP3, tissue inhibitor of 
metalloproteinase 3; TSP1, thrombospondin 1; uPAR, plasminogen activator, 
urokinase receptor; ZEB1/2, zinc-finger E-box binding homeobox 1
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Figure 5. A) The plot represents the short RNA contig for the miR-17-92 cluster on 
chromosome 13. This miRNA cluster is regulated by Myc22, 23 and is activated in 
adenocarcinoma. Each line in the plot represents a different sample (cancer in 
black and normal colon in red). All 6 miRNAs in the locus were correctly identified, 
as indicated by the UCSC annotation in red. The EvoFold prediction shows that 
the lighter green areas separate the two peaks, corresponding to the mature and 
star forms). B) The expression range of the different short RNA classes in cancer 
and normal colon. The RPKMM indicates the RNA level for each differentially 
expressed shortig. C) The pie chart shows the distribution of the differentially 
expressed RNA contigs according to their annotation classes. miRNAs account for 
less than 50% of the non-coding short RNA 
 
Figure 6. Cluster analysis of short RNA contigs differentially expressed in 
colon adenocarcinoma (t-test, p-value<0.01). Annotations are according to 
UCSC hg19 assembly. Antisense RNAs are indicated ‘as’ after the gene symbol. 
Non annotated loci are indicated just by the chromosomal location.  
 
Figure 7. Cumulative RPKMM short RNA contig plots for two miRNAs, a 
snoRNA and a piRNA. All the plots for the 129 significant shortigs in colon 
adenocarcinoma are available online at http://aqua.unife.it/ShortigShapes. miR-21 
and miR-135b are up-regulated microRNAs in cancer, while the piR-51810 piRNA 
is down-regulated. SNORD19B.2-201 is depicted in the bottom right plot and is 
over-expressed. Fold-changes indicated in the figure are for unpaired comparison. 
 
Figure 8. Small RNA Pipeline and PASS scatter plot 
The fold changes of differentially expressed miRNAs are very consistent across 
the two profile determined by the two different methods implemented for colon 
adenocarcinoma (adjusted R square = 0.96). The ABI Life Technologies small 
RNA pipeline method is indicated as SRP.  
 
Figure 9. Ends usage in the distinct differentially regulated miR-21 
isomiRNAs. The mature miR-21 form as reported in miRBase extends from 
chromosome 17:57918634 to 57918655 with a length of 22 nt.  While the most 
commonly used end is at 57918655, most of the 5’ends are either on the mature 
form or 1-2 nucleotides 3’. Thus at the 5’ end, the seed region is either identical to 
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the standard miR-21 or generally 1 to 2 nucleotides shorter. This isomiRNAs are 
therefore expected to have very similar biological activity to that of the mature 
form. Strikingly the most used 3’ end is 1 nt 3’ of the canonical site. The frequency 
indicated on the bar does not correlate to the RPMM of the relative reads, but to 
the usage in the distinct isomiRNAs. 
 
Figure 10. Ends usage in the distinct differentially regulated miR-145 
isomiRNAs. The mature miR-145 form as reported in miRBase extends from 
chromosome 5: 148810224 to 148810246 with a length of 23nt. The most 
commonly used end is at 148810224, as reported by miRBase, and most other 
5’ends are 1 or 2 nucleotides 3’. Only 1 of the 15 recorded isomiRNAs extends 1 
nucleotide longer than the canonical form. At the 5’ end, the seed region is either 
identical to the standard miR-145 or generally 1 to 2 nucleotides shorter. This 
isomiRNAs are therefore expected to have very similar biological activity to that of 
the mature form. The frequency indicated on the bar does not correlate to the 
RPMM of the relative reads, but to the usage in the distinct isomiRNAs. 
 
Figure 11. hg19 loci complexity, i.e. number of distinct reads loci per sample. 
Sample IDs are on the X axis. Shown data are for alignments with either perfect 
matching or only 1 mismatch (and 1 genomic hit). 
 
Figure 12. hg19 mapped reads complexity per sample, i.e. number of total 
counts of mapped loci. Sample IDs are on the X axis. The three worst samples 
(123, 131, 132) were excluded from the analysis. 
 
Figure 13. Measure correlations between different miRNA detection 
platforms A) SOLiD vs. Nanostring (9/10 concordant trends within CRC/Normal ) 
R = 0.98, p-value =2.73E-12 B) SOLiD vs. stem loop RT-PCR (7/9 concordant 
trends within CRC/Normal) R = 0.51, p-value =0.06 C) Nanostring vs. RTPCR (7/9 
concordant trends within CRC/Normal ) R = 0.41, p-value =0.15 
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Tables 
 
Table 1. Recurrent somatic mutations in oncogenes and tumor-suppressor genes 
in colorectal cancer (CIMP, CpG island hypermethylation phenotype; CRC, 
colorectal cancer; MSI-H, high-frequency microsatellite instability; MSS, 
microsatellite stability). 
 
Table 2. Short non-coding RNA contigs discriminate colon adenocarcinoma from 
normal colon. Paired t-test was performed on 254 RNA shortigs identified by 2969 
short RNA reads with p-value <0.01. Among them, 129 shortigs had diagnostic 
values in colon adenocarcinoma with a miclassification error of less than 0.01 and 
are listed in Table 1. RPKMM were used for quantification (reads per kb per million 
miRNAs). Although the alignment pipeline did exclude reads mapping to multiple 
loci, a filter for repetitive elements was performed by using RepeatMasker. As a 
quality control check, only samples with runs of more than 1 reads million matched 
to hg19 were used in the statistical analysis. 
Table 3. Differentially expressed miRNAs in colon adenocarcinoma, as 
determined by the small RNA pipeline (SRP) and PASS. miRNAs were identified 
by next generation sequencing using the small RNA pipeline (Life Technologies, 
Foster City) with perfect match and miRBase precursor sequences (p-values 
<0.01). Fold change is the ratio of geometric means of reads RMPM (per million) 
after quantiles normalization. Mature and isomiRNA forms are annotated 
according to miRBase 16. miRNAs are sorted by fold changes between tumor and 
normal tissues. Only perfect matches were recorded (no mismatches allowed). 
Multivariate permutations test was computed based on 1000 random permutations 
and parametric p-values are reported, alongside false detection rates (FDR). The 
isomiRNAs corresponding to the mature form, as reported by miRBase, are 
shown. Additional isomiRNAs are listed when more expressed or had higher fold 
changes than the mature form. Only the isomiRNAs detected by both the small 
RNA (SRP) and the PASS pipelines are listed. In particular, the PASS pipeline 
produced an expression matrix with 3630 different isomiRNAs, after filtering 
(threshold of 5 RPMM and a minimum presence in 25% of the samples). Of these, 
2289 were retained after filtering, when less than 20 % of expression data have at 
least a 1.5 -fold change in either direction from isomiRNA’s median value. Only 
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very few genes had values, which average, was below threshold in one of the two 
classes. When quantiles normalization was performed on the top of RPMM counts, 
2280 short RNAs were retained after filtering (9/2289 = 0.4% less than without 
quantiles normalization). Quantiles normalization yielded 393 significant miRNAs 
at p<0.01 and FDR <0.01, slightly more than without normalization. Overall we 
decided to use quantiles normalization after RPMMstandardization, as all the 
parameters indicated an improvement. When using the small RNA pipeline by Life 
Technologies, again with no mismatches, we identified 1538 isomiRNAs and 256 
isomiRNAs with p-value < 0.01. 
 
Table 4. miRNA annotation discrepancies with miRBase. The expression plots for 
along each precursor miRNA in the colon samples, subdivided in the discrepancy 
classes, can be downloaded at http://aqua.unife.it/ShortigShapes. In the cases of 
wrong strand of precursor, the count profiles were plotted for each of the two 
strands. 
 
Table 5. The performance of colon adenocarcinoma classification using the short 
non-coding RNA signature. Leave-one-out cross-validation method was used to 
compute the misclassification rate. 
 
Table 6. Colon adenocarcinoma and normal colon miRNA quantification using 
different detection techniques (average values). Values indicate averages in each 
patient cohort for each platform. SOLiD is cohort 1, Nanostring, RT-PCR, Northern 
blot are platform 2 and Microarrays are cohort 3. Cohort 3 has benign adenomas 
as controls, in place of normal colon samples. miRNAs with discordant trends are 
highlighted in yellow. The difference in the miR-145 levels between 
adenocarcinoma and benign adenoma might be related to early epigenetic 
differences between adenomas and normal colon tissues. 
 
Table 7. Correspondence between over-expressed non-coding RNAs and 
amplification by CGH in cancer (Progenetix database87). The table lists only the 
loci for which at least 3 fold excess of amplification over deletion were reported in 
the same cytoband. 
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Figure 1. Roche 454 GS FLX sequencing. 
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Figure 2. Illumina Genome Analyzer sequencing. 
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Figure 3. Applied Biosystems SOLiD sequencing by 
ligation. 
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Figure 4. The role of microRNAs (miRNAs) in colorectal 
cancer (CRC) pathogenesis. 
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Figure 5. RNA Shortigs in colorectal adenocarcinomas 
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Figure 6. Cluster analysis of short RNA contigs differentially 
expressed in colon adenocarcinoma (t-test, p-value<0.01). 
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Figure 7. Cumulative RPKMM short RNA contig plots 
for two miRNAs, a snoRNA and a piRNA. 
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Figure 8. Small RNA Pipeline and PASS Scatter Plot 
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Figure 9. Ends usage in the distinct differentially 
regulated miR-21 isomiRNAs. 
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Figure 10. Ends usage in the distinct differentially 
regulated miR-145 isomiRNAs. 
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Figure 11. hg19 loci complexity 
Figure 12. hg19 mapped reads complexity per sample 
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Figure 13. Measure correlations between different 
miRNA detection platforms 
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Table 1. Recurrent somatic mutations in oncogenes 
and tumor-suppressor genes in colorectal cancer 
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Table 2. Short non-coding RNA contigs discriminate colon adenocarcinoma 
from normal colon. 
Permutat. 
p-value  
FDR  
Geom 
mean of 
RPKMM 
in CRC  
Geom mean 
of RPKMM 
in normal 
colon  
Fold-
change 
(in paired 
samples)  
Unique id  
0.0035 0.0141 2698.2 167.84 16.85 
hsa-mir-135b|DM004220|Contig:chr1:205417451-
205417511-|201|1q32.1 
1e-04 0.00874 20109.25 1273.26 14.42 
hsa-mir-31|LOC554202|Contig:chr9:21512118-
21512178-|991|9p21.3 
0.011 0.0476 265.21 39.27 6.95 
NAV3|Contig:chr12:78591903-
78591976+|135|12q21.2 
0.0017 0.0165 35.96 5 6.66 DPYDas|Contig:chr1:98085664-98085897+|40|1p21.3 
0.0012 0.0114 84.61 12.97 6.63 
DPP10|Contig:chr2:116080149-
116080315+|102|2q14.1  
0.0012 0.0141 173.77 26.67 6.63 
DNAJC11as|Contig:chr1:6704628-
6704759+|226|1p36.31  
0.0112 0.0396 161.37 27.08 5.66 
hsa-mir-503|MGC16121|Contig:chrX:133680362-
133680443-|83|Xq26.3 
0.001 0.00874 46.14 9.01 5.44 NTM|Contig:chr11:131767619-131767837+|27|11q25  
0.0069 0.0772 370.89 68.75 5.35 Contig:chr1:71163226-71163286+|37|1p31.1  
0.0168 0.0427 60.89 10.09 5.22 Contig:chr8:91319432-91319523+|82|8q21.3  
0.0122 0.0427 497.04 107.86 4.82 
HBII-99|C20orf199|Contig:chr20:47897225-
47897303+|740|20q13.13 (SNORD12) 
6e-04 0.017 2086.07 528.36 4.71 
hsa-mir-183|DM004436|Contig:chr7:129414766-
129414828-|355|7q32.2 
5e-04 0.00836 249530.61 53513.51 4.4 
hsa-mir-21|DM119428|Contig:chr17:57918609-
57918728+|2808|17q23.1 
0.0036 0.0138 81.58 20.34 4.33 Contig:chr2:120046346-120046439+|45|2q14.2  
6e-04 0.00874 4965.72 1321.4 4.23 
hsa-mir-182|DQ595899|Contig:chr7:129410247-
129410329-|387|7q32.2 
0.0188 0.0481 107 26.85 4.05 Contig:chr4:145226185-145226296-|59|4q31.21 
0.0033 0.0211 36.68 9.41 4.02 Contig:chr4:31160576-31160713+|49|4p15.1  
0.0033 0.0332 41.86 11.06 4.01 Contig:chrX:125606345-125606856-|1238|Xq25 
0.0226 0.055 1056.97 288.37 4 Contig:chr1:95751777-95751856+|154|1p21.3  
0.0112 0.0476 509.75 144.92 3.87 
GNL3|Contig:chr3:52722906-52722969+|161|3p21.1 
SNORD19B.2-201 
0.0328 0.0874 2712.94 821.82 3.78 hsa-mir-7-2|DL233857|Contig:chr15:89155087-
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89155148+|532|15q26.1 
0.0021 0.0127 393.91 105.95 3.46 
hsa-mir-542|no UCSC|Contig:chrX:133675393-
133675453-|165|Xq26.3 
0.0125 0.0358 757.3 238.96 3.38 Contig:chr4:149864853-149864937-|83|4q31.23  
0.0505 0.0945 313.82 94.6 3.36 
mgh28S-2411|TAF1D|Contig:chr11:93464671-
93464739-|2013|11q21  
0.0207 0.055 67.5 21.53 3.22 
U48|C6orf48|Contig:chr6:31802953-
31803094+|411|6p21.33 (SNORD48) 
0.0034 0.0531 183.7 64.89 3.2 
hsa-mir-301b|no UCSC|Contig:chr22:22007279-
22007339+|125|22q11.21 
0.0148 0.0439 135.98 43.19 3.09 Contig:chr12:67479721-67479859-|127|12q14.3  
0.0102 0.0758 397.51 131.27 3.04 
SNORD123|SNORD123|Contig:chr5:9548950-
9549016+|157|5p15.31  
0.044 0.0764 238.29 77.99 2.97 
TNPO1as|Contig:chr5:72112291-72112420-
|74|5q13.2  
0.0419 0.074 80.41 27.99 2.9 
AlphaTFEB|Contig:chr11:65273440-
65273625+|153|11q13 .1  tRNA-like small RNA 
0.007 0.0465 368.64 144.1 2.89 
U78|GAS5|Contig:chr1:173834685-173834912-
|1691|1q25.1 (SNORD 78) 
0.0012 0.0114 341020.75 127487.84 2.82 
hsa-mir-
29a|CR618431as|Contig:chr7:130561503-
130561567-|2760|7q32.3 
0.0187 0.0681 775.13 264.34 2.8 
RMRP|Contig:chr9:35657748-35658017-
|1396|9p13.3  
0.001 0.00874 4403.7 1668.82 2.6 
hsa-mir-424|DM004809|Contig:chrX:133680672-
133680749-|360|Xq26.3 
0.023 0.0587 445.01 181.12 2.6 
U54|RPS20|Contig:chr8:56986395-56986461-
|1073|8q12.1 (U54 small nucleolar RNA, C/D box 
54) 
0.0047 0.0192 2722.5 1126.25 2.55 
IGF2BP3as|Contig:chr7:23403166-
23403283+|425|7p15.3  
0.0015 0.0165 87.27 35.99 2.5 PKN2|Contig:chr1:89273813-89273899+|52|1p22.2  
0.0366 0.0747 158.44 67.67 2.43 
MBNL1|Contig:chr3:152171516-
152171596+|53|3q25.2  
0.0096 0.0465 351.36 145.23 2.4 
EXOC4|Contig:chr7:133294036-
133294151+|200|7q33  
3e-04 0.00874 3486.17 1600.76 2.39 
hsa-mir-452|GABRE|Contig:chrX:151128110-
151128171-|251|Xq28 
0.0535 0.0945 701.67 336.19 2.38 NEGR1|Contig:chr1:72028786-72028897-|238|1p31.1  
0.0259 0.0626 102.45 49.6 2.3 SAMD13|Contig:chr1:84774303-
 59 
84774485+|138|1p31.1  
0.0462 0.0851 5293.22 2374.46 2.24 
COL25A1as|Contig:chr4:109814955-
109815022+|541|4q25  
0.0304 0.0764 1813.87 909.69 2.21 RIMS1|Contig:chr6:73094787-73094904+|453|6q13  
0.0379 0.0758 857.67 419.48 2.16 
MAPK10as|Contig:chr4:87139084-
87139183+|304|4q21.3  
0.0073 0.0476 96.72 48.37 2.13 
OC90|Contig:chr8:133070320-133070492-
|189|8q24.22  
0.0361 0.0764 1193.81 603.93 2.08 
ZNF639|Contig:chr3:179041259-
179041338+|201|3q26.33  
0.0349 0.0711 670.69 352.46 2.05 
C14orf106as|Contig:chr14:45707338-
45707417+|125|14q21.2  
0.0021 0.0116 274428.61 114525.36 2.01 
hsa-mir-223|mir-223|Contig:chrX:65238737-
65238805+|3057|Xq12 
0.0429 0.0874 1086.09 569.25 1.99 
C1GALT1|Contig:chr7:7222241-
7222309+|338|7p22.1  
0.0228 0.0531 567.14 307.86 1.92 
MAML2as|Contig:chr11:95805368-
95805452+|109|11q21  
0.0215 0.0614 333.57 183.66 1.87 Contig:chr5:102929579-102929698+|198|5q21.2  
0.0456 0.0874 18108.22 10626.54 1.77 
hsa-mir-210|AK123483|Contig:chr11:568109-
568191-|1025|11p15.5 
0.0035 0.0193 26820.93 15978.52 1.72 
hsa-mir-25|MCM7|Contig:chr7:99691191-99691460-
|2652|7q22.1 
0.0128 0.0476 1495.81 907.99 1.67 
hsa-mir-18b|no UCSC|Contig:chrX:133304072-
133304136-|207|Xq26.2 
0.0074 0.0531 50602.77 32689.47 1.65 
hsa-mir-17|C13orf25 v_1|Contig:chr13:92002871-
92003640+|10892|13q31.3 
0.0293 0.0632 11044.19 7602.76 1.49 
hsa-mir-455|COL27A1|Contig:chr9:116971728-
116971789+|680|9q32 
0.0132 0.0374 43915.07 31734.6 1.48 
hsa-mir-34a|EF609116|Contig:chr1:9211749-
9211817-|1268|1p36.22 
0.0347 0.076 210.81 146.56 1.46 
CNTN5|Contig:chr11:99340489-
99340585+|116|11q22.1  
0.0206 0.0547 21903.25 31146.21 0.75 
hsa-mir-30d|DL231865|Contig:chr8:135817121-
135817187-|1225|8q24.22 
0.0196 0.0531 33454.87 49179.49 0.71 
hsa-let-7g|WDR82|Contig:chr3:52302294-52302375-
|2126|3p21.1 
0.0035 0.0531 66171.79 98154.65 0.7 
hsa-mir-29c|EU154352|Contig:chr1:207975207-
207975289-|2633|1q32.2 
0.0236 0.0592 11203.91 16475.98 0.7 hsa-mir-27b|C9orf3|Contig:chr9:97847717-
 60 
97847811+|865|9q22.32 
0.0185 0.0513 31263.99 44951.36 0.69 
hsa-mir-26a-2|CTDSP2|Contig:chr12:58218401-
58218509-|1382|12q14.1 
0.02 0.0547 12261.58 17633.12 0.69 
hsa-mir-30e|NFYC|Contig:chr1:41220042-
41220109+|1983|1p34.2 
0.0288 0.0675 21684.21 31899.16 0.69 
hsa-mir-101-1|DM004381|Contig:chr1:65524121-
65524202-|1526|1p31.3 
0.0313 0.0697 29642.04 43478.06 0.69 
hsa-mir-101-2|RCL1|Contig:chr9:4850309-
4850369+|1286|9p24.1 
0.0043 0.00958 7429.98 11020.66 0.67 THRB|Contig:chr3:24318273-24318349-|482|3p24.2  
0.0189 0.0546 48447.78 72786.57 0.67 
hsa-mir-574|FAM114A1|Contig:chr4:38869677-
38869739+|1397|4p14 
0.0228 0.055 566.19 831.26 0.67 
hsa-mir-766|SEPT6|Contig:chrX:118780723-
118780803-|694|Xq24 
0.0231 0.0589 48359.11 76764.62 0.66 
hsa-mir-126|EGFL7|Contig:chr9:139565050-
139565129+|1268|9q34.3 
0.0029 0.0127 51540.85 78901.72 0.65 
hsa-mir-140|WWP2|Contig:chr16:69967005-
69967071+|3293|16q22.1 
0.0053 0.0203 660.77 1048.59 0.64 Contig:chr11:128169158-128169268+|69|11q24.3  
8e-04 0.00874 18155.8 35920.96 0.54 
hsa-mir-30b|DM004172|Contig:chr8:135812756-
135812856-|1185|8q24.22 
0.0179 0.0531 173.02 329.15 0.54 
CDKAL1|Contig:chr6:20962410-
20962533+|339|6p22.3  
0.0059 0.0192 11665.82 22794.29 0.53 
CPA6|Contig:chr8:68497631-68497751-
|9312|8q13.2 piRNA piR-51810 
0.0012 0.00874 12852.72 25320.18 0.52 
hsa-mir-30c-1|NFYC|Contig:chr1:41222948-
41223032+|1565|1p34.2 
5e-04 0.00874 4842.86 9787.8 0.5 
hsa-mir-30a|DM119476|Contig:chr6:72113256-
72113338-|495|6q13 
0.0165 0.0531 1754.78 3675.42 0.5 Contig:chr1:233917132-233917242+|201|1q42.2  
0.0147 0.0427 133673.79 264827.3 0.49 
hsa-mir-143|LOC728264|Contig:chr5:148808487-
148808565+|973|5q32 
6e-04 0.00874 8590.34 18134.65 0.48 
hsa-mir-30c-2|DM004170|Contig:chr6:72086666-
72086748-|1274|6q13 
0.0059 0.0203 1021.62 2117.51 0.48 Contig:chr2:101260946-101261043-|126|2q11. 
4e-04 0.00874 484.84 1006.14 0.47 
IGSF21|Contig:chr1:18627390-
18627531+|188|1p36.13  
0.0368 0.0745 128.36 280.09 0.46 Contig:chr3:117186707-117186828+|99|3q13.31  
0.0026 0.0141 592371.61 1341828.71 0.43 
hsa-mir-145|LOC728264|Contig:chr5:148810222-
148810286+|1980|5q32 
 61 
0.0063 0.0203 1235.79 2731.32 0.43 Contig:chr2:55717350-55717439+|81|2p16. 
0.0245 0.0758 18971.83 62582.06 0.41 
hsa-mir-215|IARS2as|Contig:chr1:220291218-
220291278-|543|1q41 
0.0011 0.0114 24.78 57.74 0.4 
LENG8|Contig:chr19:54969382-
54969562+|69|19q13.42  
0.0017 0.0114 167.43 368.94 0.4 
NEBLas|Contig:chr10:21338351-
21338478+|204|10p12.31  
7e-04 0.0192 723.04 2264.05 0.4 
SLC1A7as|Contig:chr1:53561108-
53561233+|116|1p32.3  
0.0321 0.071 2567.62 6095.22 0.4 
hsa-mir-3065as|AATK|Contig:chr17:79099685-
79099746-|513|17q25.3 
2e-04 0.00874 5176.84 13599.17 0.39 
hsa-mir-10b|DM004331|Contig:chr2:177015057-
177015121+|1195|2q31.1 
0.0032 0.017 806.48 1977.92 0.39 
AK311257as|Contig:chr8:142405380-142405453-
|108|8q24.3  
0.0026 0.0138 6542.9 16867.98 0.36 
PDGFC|Contig:chr4:157834741-157834874-
|243|4q32.1  
3e-04 0.0476 362.9 968.71 0.36 
hsa-mir-511-1|MRC1|Contig:chr10:17887121-
17887181+|154|10p12.33 
3e-04 0.0476 362.9 968.71 0.36 
hsa-mir-511-2|MRC1|Contig:chr10:18134050-
18134110+|154|10p12.33 
0.01 0.0587 144.97 388.46 0.34 
CTNNA3|Contig:chr10:68504527-68504640-
|152|10q21.3  
0.0066 0.0657 77.19 238.65 0.34 AF086303|Contig:chr6:74832055-74832154+|39|6q13  
0.0012 0.0268 43.73 120.91 0.33 
GRSF1as|Contig:chr4:71702781-
71702900+|87|4q13.3  
0.0507 0.0945 228.4 666.75 0.33 
CALD1|Contig:chr7:134630474-
134630553+|104|7q33  
0.0373 0.0758 21.86 63.34 0.32 
C14orf25|Contig:chr14:38091955-
38092100+|23|14q21.1  
0.0061 0.0975 3957.24 12273.91 0.32 
hsa-mir-195|DM004261|Contig:chr17:6920946-
6921007-|611|17p13.1 
0.0028 0.095 1786.95 5501.52 0.31 
hsa-mir-218-1|SLIT2|Contig:chr4:20529922-
20529983+|308|4p15.31 
0.0054 0.0681 320.95 1050.77 0.3 
hsa-mir-149|GPC1|Contig:chr2:241395374-
241395475+|226|2q37.3 
0.0376 0.0711 132.83 429.73 0.3 
CCBL2as|Contig:chr1:89454772-
89454870+|124|1p22.2  
0.0317 0.0711 36.64 124.12 0.3 KCNQ3as|Contig:chr8:133486556-
 62 
133486687+|70|8q24.22  
0.0051 0.0427 21.28 77.71 0.28 
AKAP6as|Contig:chr14:32953303-32954323-
|3013|14q12  
0.0045 0.0587 410.29 1440.61 0.27 Contig:chr3:141176313-141176374-|39|3q23  
0.0044 0.0614 863.68 3271.92 0.27 
hsa-mir-138-2|DM004413|Contig:chr16:56892439-
56892507+|331|16q13 
3e-04 0.0114 116.08 502.99 0.26 Contig:chrX:152237951-152238082+|107|Xq28  
3e-04 0.0114 116.08 502.99 0.26 Contig:chrX:152335414-152335545+|107|Xq28  
3e-04 0.0114 116.08 502.99 0.26 Contig:chrX:152346176-152346307-|107|Xq28  
3e-04 0.0192 93.43 359.79 0.26 
ACA54|NAP1L4|Contig:chr11:2985007-2985124-
|1224|11p15.4 (H/ACA Box snoRNA) 
0.0028 0.0531 736.48 2911.79 0.25 
hsa-mir-138-1|DM004414|Contig:chr3:44155704-
44155787+|409|3p21.32 
0.0012 0.0114 9.37 36.8 0.23 CLK1|Contig:chr2:201728724-201728865-|40|2q33.1  
0.0119 0.0476 25.3 101.55 0.22 MYT1L|Contig:chr2:1972719-1972780-|73|2p25.3  
0.0045 0.0233 10.3 53.22 0.2 
KALRNas|Contig:chr3:124068655-124068789-
|20|3q21.2  
0.0012 0.0138 62.93 358.71 0.18 NUBPLas|Contig:chr14:32313881-32313962-
|32|14q12   
0.0103 0.033 76.62 439.66 0.15 
Contig:chr10:69524258-69524366+|629|10q21.3 
Possible tRNA 
4e-04 0.00874 23.61 158.02 0.14 
hsa-mir-551b|no UCSC|Contig:chr3:168269580-
168269724+|233|3q26.2 
4e-04 0.00874 38.77 334.94 0.14 
hsa-mir-9-3|LOC254559|Contig:chr15:89911263-
89911324+|131|15q26.1 
4e-04 0.0203 94.79 610.21 0.14 
hsa-mir-204|TRPM3|Contig:chr9:73424848-
73424968-|204|9q21.12 
0.0074 0.0306 670.58 4354.08 0.14 
hsa-mir-1-1|C20orf166|Contig:chr20:61151518-
61151581+|178|20q13.33 
2e-04 0.00874 26.47 230.09 0.13 
hsa-mir-129-2|DM004400|Contig:chr11:43602958-
43603022+|91|11p11.2 
4e-04 0.00874 40.32 370.3 0.13 
hsa-mir-9-1|C1orf61|Contig:chr1:156390144-
156390206-|141|1q22 
4e-04 0.00874 42.59 384.46 0.13 
hsa-mir-9-2|LOC645323|Contig:chr5:87962682-
87962742-|143|5q14.3 
6e-04 0.0124 58.2 399 0.13 Contig:chr4:160867890-160867958+|71|4q32.1 
< 1e-07 0.00874 103.83 1502.1 0.087 
hsa-mir-147b|C15orf48|Contig:chr15:45725295-
45725364+|144|15q21.1 
 63 
0.0025 0.0114 8.37 100.42 0.087 
hsa-mir-129-1|DM004399|Contig:chr7:127847929-
127847995+|36|7q32.1 
 64 
 
Table 3. Differentially expressed miRNAs in colon adenocarcinoma, as 
determined by the small RNA pipeline (SRP) and PASS.  
p-value 
(SRP) 
 
FDR 
(SRP) 
Geom 
mean of 
RPMM in 
colon 
adeno-
carcinoma 
(SRP) 
Geom 
mean of 
RPMM 
in 
normal 
colon 
(SRP) 
Fold-
change 
(SRP) 
Fold Change 
(PASS) 
Chromosomal 
coordinates 
miRNA 
8.7e-06 0.000892 362.31 18.7 19.37 18.75 
hsa-mir-
31@9:21512156-
21512177 22(-)ncl:1 
hsa-
mir-31 
6.53e-05 0.00279 866.85 79.13 10.95 11.45 
hsa-mir-
31@9:21512157-
21512177 21(-)mature 
hsa-
miR-31 
0.0081944 0.0531 1903.77 175.2 10.87 8.69 
hsa-mir-
21@17:57918634-
57918656 23(+)ncl:1 
hsa-
mir-21 
0.0028611 0.0287 23622.22 2839.43 8.32 4.39 
hsa-mir-
29a@7:130561507-
130561528 22(-
)mature 
hsa-
miR-
29a 
0.0002439 0.00708 140.08 17.82 7.86 7.67 
hsa-mir-
135b@1:205417489-
205417511 23(-
)mature 
hsa-
miR-
135b 
2.36e-05 0.00173 394.61 74.04 5.33 5.33 
hsa-mir-
224@X:151127102-
151127123 22(-)ncl:1 
hsa-
mir-
224 
1.03e-05 0.000968 85.35 18.39 4.64 
hsa-mir-
222@X:45606443-
45606462 20(-) ncl:-
1 FC= 2.44 
hsa-mir-
222@X:45606440-
45606462 23(-)ncl:2 
hsa-
mir-
222 
2e-06 0.000342 43.84 10.5 4.17 4.48 
hsa-mir-
224@X:151127103-
151127123 21(-
)mature 
hsa-
miR-
224 
0.0017424 0.0225 349.81 100.72 3.47 3.39 
hsa-mir-
182@7:129410287-
129410310 24(-
hsa-
miR-
182 
 65 
)mature 
0.001873 0.0227 163.08 56.95 2.86 2.26 
hsa-mir-199a-
1@19:10928105-
10928127 23(-) 
hsa-
mir-
199a-1 
0.002398 0.0269 55.07 19.41 2.84 2.31 
hsa-mir-
183@7:129414806-
129414827 22(-) 
hsa-
mir-
183 
5.34e-05 0.00259 3394.71 1283 2.65 2.48 
hsa-mir-
21@17:57918635-
57918656 22(+) 
hsa-
mir-21 
7.34e-05 0.00289 751.43 290.27 2.59 2.2 
hsa-mir-
25@7:99691194-
99691215 22(-) 
mature 
hsa-
miR-25 
0.001496 0.021 13137.08 5244.31 2.51 2.45 
hsa-mir-
223@X:65238779-
65238800 
22(+)mature 
hsa-
miR-
223 
0.0009978 0.0163 8333.54 3411.05 2.44 2.48 
hsa-mir-
223@X:65238779-
65238801 23(+)ncl:1 
hsa-
mir-
223 
0.0066569 0.047 46.16 19.36 2.38 2.6 
hsa-mir-
1247@14:102026699-
102026720 22(-
)mature 
hsa-
miR-
1247 
0.0017122 0.0223 3676.75 1542.77 2.38 2.11 
hsa-mir-
17@13:92002872-
92002892 21(+)ncl:-2 
hsa-
mir-17 
0.0002082 0.00658 1633.86 698.22 2.34 2.16 
hsa-mir-
20a@13:92003326-
92003346 21(+)ncl:-2 
hsa-
mir-
20a 
0.0008038 0.0138 100.42 42.85 2.34 2.04 
hsa-mir-
301a@17:57228509-
57228532 24(-)ncl:1 
hsa-
mir-
301a 
0.0030172 0.0288 236.34 102.7 2.3 2.38 
hsa-mir-
424@X:133680711-
133680731 21(-)ncl:-1 
hsa-
mir-
424 
0.0003488 0.00838 1535.96 702.85 2.19 2.35 
hsa-mir-
18a@13:92003010-
92003032 
23(+)mature 
hsa-
miR-
18a 
0.003218 0.0302 13539.22 6614.35 2.05 2.0 hsa-mir- hsa-
 66 
17@13:92002872-
92002894 
23(+)mature 
miR-17 
0.0051651 0.042 36.02 18.41 1.96 
hsa-mir-
455@9:116971768-
116971787 20(+)ncl:-
2 FC 2.12 
hsa-mir-
455@9:116971766-
116971787 22(+) 
hsa-
mir-
455 
0.0014047 0.0202 28.14 14.47 1.94 1.36 
hsa-mir-
487a@14:101518831-
101518852 
22(+)mature 
hsa-
miR-
487a 
2.33e-05 0.00173 5635.89 3003.41 1.88 
2.01 (substantial 
difference in RPMM) 
hsa-mir-
23a@19:13947407-
13947429 23(-)ncl:2 
hsa-
mir-
23a 
0.0096939 0.0587 184.73 100.88 1.83 1.79 
hsa-mir-
452@X:151128150-
151128171 22(-
)mature 
hsa-
miR-
452 
0.0065205 0.0464 16.96 10 1.7 
hsa-mir-
552@1:35135216-
35135235 20(-)ncl:-1 
FC 2.03 
hsa-mir-
552@1:35135215-
35135236 22(-)ncl:1 
hsa-
mir-
552 
0.0042764 0.0361 62.5 37.85 1.65 
hsa-mir-
494@14:101496018-
101496039 
22(+)mature FC 1.54 
hsa-mir-
494@14:101496018-
101496038 21(+)ncl:-1 
hsa-
mir-
494 
0.0096361 0.0587 236.89 152.99 1.55 
hsa-mir-92a-
1@13:92003615-
92003636 
22(+)mature FC 1.63 
hsa-mir-92a-
1@13:92003616-
92003636 21(+)ncl:-1 
hsa-
mir-
92a-1 
0.003562 0.0326 14.01 10 1.4 1.88 
hsa-mir-
106b@7:99691628-
99691646 19(-)ncl:-2 
hsa-
mir-
106b 
0.0090538 0.0571 235.74 336.12 0.7 0.68 
hsa-mir-
28@3:188406582-
188406602 21(+)ncl:-1 
hsa-
mir-28 
0.0035127 0.0324 398.7 609.36 0.65 0.62 
hsa-mir-
29c@1:207975210-
207975230 21(-)ncl:-1 
hsa-
mir-
29c 
0.0051476 0.042 4113.68 6470.64 0.64 0.68 
hsa-mir-
23b@9:97847547-
97847567 21(+) 
mature 
hsa-
miR-
23b 
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0.00937 0.0582 268.1 432.4 0.62 0.65 
hsa-mir-
30d@8:135817163-
135817183 21(-)ncl:-1 
hsa-
mir-
30d 
0.0042674 0.0361 293.22 533.37 0.55 0.52 
hsa-mir-
140@16:69967045-
69967066 22(+) 
hsa-
mir-
140 
0.0026118 0.0276 12.54 23.52 0.53 
hsa-mir-
143@5:148808541-
148808561 21(+) 
mature FC 0.45 
hsa-mir-
143@5:148808540-
148808558 19(+)ncl:-2 
hsa-
mir-
143 
0.0007865 0.0138 1776.19 3447.62 0.52 0.50 
hsa-mir-
30b@8:135812813-
135812834 22(-
)mature 
hsa-
miR-
30b 
0.0007886 0.0138 14.56 28.55 0.51 0.53 
hsa-mir-138-
2@16:56892439-
56892459 21(+)ncl:-2 
hsa-
mir-
138-2 
0.000338 0.00838 34866.92 68651.32 0.51 0.47 
hsa-mir-
145@5:148810224-
148810246 
23(+)mature 
hsa-
miR-
145 
0.006862 0.048 529.5 1077.2 0.49 0.49 
hsa-mir-30c-
1@1:41222972-
41222994 
23(+)mature 
hsa-
miR-
30c 
0.0026229 0.0276 21.39 45.69 0.47 0.56 
hsa-mir-
190@15:63116206-
63116227 22(+) 
hsa-
mir-
190 
2.5e-06 0.000385 5073.82 11329.89 0.45 0.46 
hsa-mir-
125a@19:52196521-
52196542 22(+)ncl:-2 
hsa-
mir-
125a 
0.0003146 0.00806 584.97 1336.92 0.44 0.58 
hsa-mir-26a-
1@3:38010904-
38010922 19(+)ncl:-3 
hsa-
mir-
26a-1 
0.0006179 0.0121 66.22 151.6 0.44 0.48 
hsa-mir-
28@3:188406582-
188406601 20(+)ncl:-2 
hsa-
mir-28 
0.0016075 0.0217 18.8 45.8 0.41 0.37 
hsa-mir-218-
1@4:20529922-
20529942 
21(+)mature 
hsa-
miR-
218 
0.0018569 0.0227 18.17 43.82 0.41 0.49 
hsa-mir-
221@X:45605651-
hsa-
mir-
 68 
45605670 20(-)ncl:-3 221 
0.0009366 0.0155 19.2 49.1 0.39 0.43 
hsa-mir-
149@2:241395432-
241395454 
23(+)mature 
hsa-
miR-
149 
0.0030133 0.0288 40.4 104.46 0.39 0.41 
hsa-mir-29b-
1@7:130562229-
130562249 21(-)ncl:-2 
hsa-
mir-
29b-1 
0.0006389 0.0121 1060.9 2738.76 0.39 0.33 
hsa-mir-
378@5:149112430-
149112450 
21(+)mature 
hsa-
miR-
378 
5.39e-05 0.00259 174.5 463.98 0.38 0.31 
hsa-mir-
378c@10:132760901-
132760921 21(-)ncl:-4 
hsa-
mir-
378c 
0.0002963 0.00786 262.92 702.03 0.37 0.36 
hsa-mir-
10b@2:177015057-
177015078 22(+)ncl:-1 
hsa-
mir-
10b 
9.07e-05 0.00332 78.23 216.81 0.36 0.38 
hsa-mir-
30a@6:72113299-
72113319 21(-)ncl:-1 
hsa-
mir-
30a 
0.0007891 0.0138 566.16 1575.27 0.36 0.35 
hsa-mir-
497@17:6921298-
6921318 21(-)mature 
hsa-
miR-
497 
8.87e-05 0.00332 11417.82 32609.4 0.35 0.44 
hsa-mir-
145@5:148810224-
148810245 22(+)ncl:-1 
hsa-
mir-
145 
0.0013086 0.0192 100.82 290.54 0.35 0.34 
hsa-mir-
192@11:64658632-
64658654 23(-)ncl:2 
hsa-
mir-
192 
0.0023399 0.0266 437.33 1309.05 0.33 0.33 
hsa-mir-
150@19:50004089-
50004110 22(-)mature 
hsa-
miR-
150 
4.5e-06 0.000628 11.49 36.96 0.31 0.35 
hsa-mir-
147b@15:45725296-
45725318 23(+)ncl:1 
hsa-
mir-
147b 
1.3e-06 0.00025 2431.76 7891.04 0.31 0.31 
hsa-mir-
378@5:149112430-
149112451 22(+)ncl:1 
hsa-
mir-
378 
4.13e-05 0.0023 22.8 80.87 0.28 0.34 
hsa-mir-138-
1@3:44155726-
44155749 24(+)ncl:1 
hsa-
mir-
138-1 
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0.0001377 0.00471 16.74 60.53 0.28 0.37 
hsa-mir-
204@9:73424947-
73424968 22(-)mature 
hsa-
miR-
204 
0.0007098 0.0132 53.07 203.44 0.26 0.3 
hsa-mir-
338@17:79099687-
79099708 22(-) 
hsa-
mir-
338 
6.47e-05 0.00279 58.2 231.64 0.25 0.27 
hsa-mir-
139@11:72326147-
72326168 22(-)mature 
hsa-
miR-
139-5p 
0.0053629 0.0431 325.54 2100.76 0.15 0.16 
hsa-mir-
215@1:220291257-
220291278 22(-)ncl:1 
hsa-
mir-
215 
0.0025041 0.0273 154.67 1047.92 0.15 0.17 
hsa-mir-
215@1:220291258-
220291278 21(-
)mature 
hsa-
miR-
215 
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Table 4. miRNA annotation discrepancies with miRBase. 
miRNA            (- indicates antisense) Discrepancy 
hsa-let-7c star form with wrong coordinates 
hsa-mir-100 not detectable star form 
hsa-mir-103-1 miRNA with un-annotated star form 
hsa-mir-103-1-as- miRNA with un-annotated star form 
hsa-mir-103-2-as- miRNA with un-annotated star form 
hsa-mir-107 miRNA with un-annotated star form 
hsa-mir-1-1 miRNA with un-annotated star form 
hsa-mir-1185-1 wrong mature coordinates 
hsa-mir-1201 major/star forms swap 
hsa-mir-1234 wrong mature coordinates 
hsa-mir-1248 aberrant precursor processing 
hsa-mir-1259 aberrant precursor processing 
hsa-mir-125a miRNA with un-annotated star form 
hsa-mir-127 miRNA with un-annotated star form 
hsa-mir-1271 miRNA with un-annotated star form 
hsa-mir-1273 aberrant precursor processing 
hsa-mir-1273- aberrant precursor processing 
hsa-mir-1273d aberrant precursor processing 
hsa-mir-1273d- aberrant precursor processing 
hsa-mir-1285-1 aberrant precursor processing 
hsa-mir-1285-1- aberrant precursor processing 
hsa-mir-129-1 major/star forms swap 
hsa-mir-129-2 major/star forms swap 
hsa-mir-1303 major/star forms swap 
hsa-mir-1306 major/star forms swap 
hsa-mir-1307 miRNA with un-annotated star form 
hsa-mir-130a star form with wrong coordinates 
hsa-mir-133a-1 miRNA with un-annotated star form 
hsa-mir-133a-2 miRNA with un-annotated star form 
hsa-mir-134 miRNA with un-annotated star form 
hsa-mir-138-2 not detectable star form 
hsa-mir-140 major/star forms swap 
hsa-mir-142 miRNA with un-annotated star form 
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hsa-mir-146b miRNA with un-annotated star form 
hsa-mir-147b miRNA with un-annotated star form 
hsa-mir-149 not detectable star form 
hsa-mir-151 miRNA with un-annotated star form 
hsa-mir-152 miRNA with un-annotated star form 
hsa-mir-154 major/star forms swap 
hsa-mir-181b-1 miRNA with un-annotated star form 
hsa-mir-181b-2 miRNA with un-annotated star form 
hsa-mir-1826 miRNA with un-annotated star form 
hsa-mir-188 miRNA with un-annotated star form 
hsa-mir-190 miRNA with un-annotated star form 
hsa-mir-193a major/star forms swap 
hsa-mir-194-1 miRNA with un-annotated star form 
hsa-mir-196a-1 miRNA with un-annotated star form 
hsa-mir-196a-2 not detectable star form 
hsa-mir-1972-1 wrong strand of precursor 
hsa-mir-1972-1- wrong strand of precursor 
hsa-mir-1972-2 wrong strand of precursor 
hsa-mir-1972-2- wrong strand of precursor 
hsa-mir-1975 aberrant precursor processing 
hsa-mir-1979 aberrant precursor processing 
hsa-mir-199a-1 miRNA with un-annotated star form 
hsa-mir-199a-2 miRNA with un-annotated star form 
hsa-mir-199b miRNA with un-annotated star form 
hsa-mir-203 miRNA with un-annotated star form 
hsa-mir-210 miRNA with un-annotated star form 
hsa-mir-2110 miRNA with un-annotated star form 
hsa-mir-212 miRNA with un-annotated star form 
hsa-mir-215 miRNA with un-annotated star form 
hsa-mir-2355 miRNA with un-annotated star form 
hsa-mir-28 miRNA with un-annotated star form 
hsa-mir-296 miRNA with un-annotated star form 
hsa-mir-299 miRNA with un-annotated star form 
hsa-mir-301a miRNA with un-annotated star form 
hsa-mir-3065 wrong strand of precursor 
hsa-mir-3065- wrong strand of precursor 
hsa-mir-3074 wrong strand of precursor 
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hsa-mir-3074- wrong strand of precursor 
hsa-mir-3120 wrong strand of precursor 
hsa-mir-3120- wrong strand of precursor 
hsa-mir-3130-1 aberrant precursor processing 
hsa-mir-3130-1- aberrant precursor processing 
hsa-mir-3130-2 aberrant precursor processing 
hsa-mir-3130-2- aberrant precursor processing 
hsa-mir-3130-3 aberrant precursor processing 
hsa-mir-3130-3- aberrant precursor processing 
hsa-mir-3145 wrong mature coordinates 
hsa-mir-3159 aberrant precursor processing 
hsa-mir-3159- aberrant precursor processing 
hsa-mir-3184- wrong strand of precursor 
hsa-mir-323 wrong mature coordinates 
hsa-mir-323b wrong mature coordinates 
hsa-mir-324 major/star forms swap 
hsa-mir-330 major/star forms swap 
hsa-mir-331 major/star forms swap 
hsa-mir-337 miRNA with un-annotated star form 
hsa-mir-339 miRNA with un-annotated star form 
hsa-mir-33a major/star forms swap 
hsa-mir-342 major/star forms swap 
hsa-mir-34b major/star forms swap 
hsa-mir-361 miRNA with un-annotated star form 
hsa-mir-362 miRNA with un-annotated star form 
hsa-mir-365-2 not detectable star form 
hsa-mir-369 miRNA with un-annotated star form 
hsa-mir-375 miRNA with un-annotated star form 
hsa-mir-376b miRNA with un-annotated star form 
hsa-mir-376c miRNA with un-annotated star form 
hsa-mir-381 miRNA with un-annotated star form 
hsa-mir-382 miRNA with un-annotated star form 
hsa-mir-409 major/star forms swap 
hsa-mir-423 major/star forms swap 
hsa-mir-4284 aberrant precursor processing 
hsa-mir-4286 aberrant precursor processing 
hsa-mir-4297- wrong strand of precursor 
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hsa-mir-452 star form with wrong coordinates 
hsa-mir-454 major/star forms swap 
hsa-mir-455 major/star forms swap 
hsa-mir-483 major/star forms swap 
hsa-mir-485 miRNA with un-annotated star form 
hsa-mir-486 aberrant precursor processing 
hsa-mir-486- aberrant precursor processing 
hsa-mir-490 major/star forms swap 
hsa-mir-500 major/star forms swap 
hsa-mir-501 miRNA with un-annotated star form 
hsa-mir-502 major/star forms swap 
hsa-mir-511-1 major/star forms swap 
hsa-mir-511-2 major/star forms swap 
hsa-mir-532 miRNA with un-annotated star form 
hsa-mir-542 major/star forms swap 
hsa-mir-548d-1 wrong mature coordinates 
hsa-mir-548d-1 wrong strand of precursor 
hsa-mir-548d-1- wrong strand of precursor 
hsa-mir-548d-2 wrong mature coordinates 
hsa-mir-548d-2- wrong mature coordinates 
hsa-mir-548h-2 wrong mature coordinates 
hsa-mir-548q wrong strand of precursor 
hsa-mir-548q- wrong mature coordinates 
hsa-mir-548q- wrong strand of precursor 
hsa-mir-548t wrong mature coordinates 
hsa-mir-548t- wrong mature coordinates 
hsa-mir-548v major/star forms swap 
hsa-mir-550-1 major/star forms swap 
hsa-mir-550-2 major/star forms swap 
hsa-mir-552 miRNA with un-annotated star form 
hsa-mir-558 wrong mature coordinates 
hsa-mir-558- wrong mature coordinates 
hsa-mir-566 wrong mature coordinates 
hsa-mir-566- wrong mature coordinates 
hsa-mir-574 major/star forms swap 
hsa-mir-574- wrong mature coordinates 
hsa-mir-582 miRNA with un-annotated star form 
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hsa-mir-582- wrong mature coordinates 
hsa-mir-590 miRNA with un-annotated star form 
hsa-mir-616 major/star forms swap 
hsa-mir-619 aberrant precursor processing 
hsa-mir-619- aberrant precursor processing 
hsa-mir-625 major/star forms swap 
hsa-mir-625- major/star forms swap 
hsa-mir-642 miRNA with un-annotated star form 
hsa-mir-652 miRNA with un-annotated star form 
hsa-mir-654 major/star forms swap 
hsa-mir-660 miRNA with un-annotated star form 
hsa-mir-671 miRNA with un-annotated star form 
hsa-mir-769 miRNA with un-annotated star form 
hsa-mir-874 miRNA with un-annotated star form 
hsa-mir-886 aberrant precursor processing 
hsa-mir-92a-2 not detectable star form 
hsa-mir-935 wrong mature coordinates 
hsa-mir-941-1 aberrant precursor processing 
hsa-mir-941-2 aberrant precursor processing 
hsa-mir-941-3 aberrant precursor processing 
hsa-mir-942 wrong mature coordinates 
hsa-mir-98 miRNA with un-annotated star form 
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Table 5. The performance of colon adenocarcinoma classification using the short 
non-coding RNA signature  
Pair ID  
Mean 
Number of 
genes in 
classifier 
Diagonal Linear 
Discriminant 
Analysis 
Correct? 
1-Nearest 
Neighbor 
3-Nearest 
Neighbors 
Correct? 
Nearest 
Centroid 
Correct?  
CRC16500 121 YES YES YES YES  
CRC580 112 YES YES YES YES  
CRC617 126 YES YES YES YES  
CRC618 144 NO YES YES YES  
CRC622 114 YES YES YES YES  
CRC680 115 YES YES YES YES  
CRC740 118 YES YES YES YES  
CRC747 113 YES YES YES YES  
CRC758 109 YES YES YES YES  
CRC766 124 YES YES YES YES  
CRC774 109 YES YES YES YES  
CRC800 116 YES YES YES YES  
CRC803 116 YES YES YES YES  
Mean percent 
of correct 
classification 
 92 100 100 100  
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Table 6. Colon adenocarcinoma and normal colon miRNA quantification using 
different detection techniques (average values)  
 
miRNA SOLiD 
RT-PCR 
(Stem-
loop) 
Microarrays 
(Adenocarcin
oma vs. 
Benign 
Adenoma) 
RT-PCR 
(LNA) 
Northern 
Blot 
NanoString 
miR-29a Control 328.17 2.46 147.04 6.16 4866397.79 7491.28 
miR-29a Cancer 2574.11 2.01 526.25 13.45 9790703.92 13026.55 
miR-31 Control 12.85 0.01 Ns   34.49 
miR-31 Cancer 97.62 0.12 Ns   140.73 
miR-135b  Control 10.00 0.02 224.61   42.74 
miR-135b  Cancer 25.4 0.22 392.36   798.77 
miR-223 Control 572.94 0.86 250.21   1200.20 
miR-223 Cancer 1432.18 1.13 2137.13   2724.59 
miR-224 Control 12.06 0.04 65.26   95.77 
miR-224 Cancer 42.62 0.14 142.17   117.97 
miR-497 Control 170.68 0.37    1154.83 
miR-497 Cancer 62.61 0.14    514.62 
miR-148a  Control 102.88 0.29 Ns   1368.73 
miR-148a Cancer 38.67 0.27 Ns   2843.71 
miR-215 Control 114.44 0.52   851396.62 424.10 
miR-215 Cancer 28.28 0.10   651444.00 224.35 
miR-378 Control 297.47 2.27    497.43 
miR-378 Cancer 114.89 0.80    193.85 
miR-145 Control 7640.96  830.76  10165254.98 57050.29 
miR-145 Cancer 3815.46  1765.8  3911435.14 21756.85 
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Table 7. Correspondence between over-expressed non-coding RNAs and 
amplification by CGH in cancer  
 
Short RNA contig 
Cases 
of 
Amplif. 
Cases 
of 
Deletion 
Fold 
A/D 
Comments 
mir-135b |Contig:chr1:205417451-205417511-
|201|1q32.1 4407 551 8.0 miRNA 
Contig:chr8:91319432-91319523+|82|8q21.3  4407 826 5.3  
HBII-99 |Contig:chr20:47897225-
47897303+|740|20q13.13  3581 551 6.5 SNORD12 
mir-183 | Contig:chr7:129414766-129414828-
|355|7q32.2 3856 826 4.7 miRNA 
mir-21 | Contig:chr17:57918609-
57918728+|2808|17q23.1 3856 1102 3.5 miRNA 
mir-182 | Contig:chr7:129410247-129410329-
|387|7q32.2 3856 826 4.7 miRNA 
Contig:chr12:67479721-67479859-
|127|12q14.3  2204 551 4  
SNORD123|SNORD123|Contig:chr5:9548950-
9549016+|157|5p15.31  2755 551 5 SNORD123 
U78|GAS5|Contig:chr1:173834685-
173834912-|1691|1q25.1  4407 275 16 SNORD78 
hsa-mir-29a|Contig:chr7:130561503-
130561567-|2760|7q32.3 3856 826 4.7 miRNA 
U54|RPS20|Contig:chr8:56986395-56986461-
|1073|8q12.1  3738 850 4.4 SNORD54 
IGF2BP3as|Contig:chr7:23403166-
23403283+|425|7p15.3  4097 623 6.6 overlap on Human EST AV729899 
MBNL1|Contig:chr3:152171516-
152171596+|53|3q25.2  2935 896 3.3 
Overlaps H- Inv v7.0 gene 
predictions (HIT000005157)  
EXOC4|Contig:chr7:133294036-
133294151+|200|7q33  3900 863 4.5  
OC90|Contig:chr8:133070320-133070492-
|189|8q24.22 5076 763 6.7 
In  a region with CTCF TFBS point 
from ENCODE 
ZNF639|Contig:chr3:179041259-
179041338+|201|3q26.33  3224 934 3.5 Burge lab RNA seq colon  
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|C1GALT1|Contig:chr7:7222241-
7222309+|338|7p22.1  3986 729 5.5 Overlaps ESTs, possibly an exon 
mir-25 |Contig:chr7:99691191-99691460-
|2652|7q22.1 4232 787 5.4 miRNA 
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